Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Cardiology›Condition·Updated Jul 11, 2026·v1

Atrial Fibrillation

Atrial fibrillation is a progressive supraventricular arrhythmia requiring a multipronged approach: stroke prevention with DOACs (apixaban preferred), symptom control via rate or rhythm management, and intensive risk factor modification. Early rhythm control reduces adverse cardiovascular outcomes, and catheter ablation improves survival in HFrEF. Anticoagulation decisions should be driven by CHA₂DS₂-VASc score, not rhythm status, and should be continued indefinitely after ablation in higher-risk patients.

High Evidence574 references·11,443 words·46 min read·v1
atrial fibrillationarrhythmiastroke preventionanticoagulationcatheter ablationDOACcardioversionrate controlrhythm controlcardiovascular

Quick Reference

RxDrug of choice[[Apixaban]] 5 mg BID (2.5 mg BID if age ≥80, weight ≤60 kg, or creatinine ≥1.5 mg/dL) for stroke prevention; [[metoprolol]] or [[diltiazem]] for acute rate control; early rhythm control with [[flecainide]]/[[propafenone]] (no structural heart disease) or [[amiodarone]] (structural disease).
AltAlternatives[[Rivaroxaban]] 20 mg daily, [[edoxaban]] 60 mg daily, [[warfarin]] (INR 2-3) for anticoagulation; [[digoxin]] for rate control in HFpEF/permanent AF; catheter ablation for rhythm control.
⊘Avoid[[Aspirin]] for stroke prevention; non-dihydropyridine CCBs in HFrEF (LVEF <40%); [[dronedarone]] in NYHA III-IV HF; class IC agents in structural heart disease.
DxTest of choice12-lead ECG showing ≥30 seconds of irregularly irregular rhythm without P waves; ambulatory monitoring (Holter, event recorder, insertable cardiac monitor) for paroxysmal AF.
ScKey score[[CHA₂DS₂-VASc]] (stroke risk: anticoagulate men ≥2, women ≥3); [[HAS-BLED]] (bleeding risk assessment, not to deny therapy).
→When to referRefer for catheter ablation: symptomatic paroxysmal AF, persistent AF after failed AADs, HFrEF with AF to improve survival; refer for LAAO if contraindication to long-term anticoagulation; refer for AV junction ablation + CRT if refractory rapid ventricular rates.
Anticoagulate with a DOAC (apixaban preferred) based on CHA₂DS₂-VASc; pursue early rhythm control within 1 year of diagnosis; aggressively modify risk factors (weight loss, BP control, alcohol reduction); use catheter ablation for symptomatic paroxysmal AF and HFrEF.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting over 10 million US adults and doubling mortality risk through stroke and heart failure. Diagnosis requires ECG documentation of ≥30 seconds of irregularly irregular rhythm with absent P waves. Management rests on three pillars: stroke prevention with direct oral anticoagulants (DOACs), symptom control via rate or rhythm strategies, and aggressive risk factor modification. Early rhythm control within one year of diagnosis reduces cardiovascular events, and catheter ablation improves survival in heart failure patients.

Overview and Recommendations

Background

  • •Atrial fibrillation (AF) is a supraventricular tachyarrhythmia defined electrocardiographically by the replacement of consistent P waves with rapid, irregular fibrillatory waves and an irregularly irregular ventricular response when atrioventricular conduction is intact. It affects approximately 37.6 million people worldwide, with prevalence rising steeply with age: <1% under 55 years to >10% in those ≥80 years.
  • •AF doubles the risk of all-cause mortality and increases stroke risk fivefold, approximately 20% of all ischemic strokes are attributable to AF. The arrhythmia also predisposes to heart failure, cognitive decline, and tachycardia-induced cardiomyopathy when ventricular rates are persistently high.
  • •Classification by temporal pattern includes first diagnosed, paroxysmal (self-terminating within 7 days), persistent (>7 days), long-standing persistent (>12 months), and permanent (rhythm control no longer pursued). The 2023 ACC/AHA staging system further defines Stage 1 (at risk), Stage 2 (pre-AF with atrial pathology), Stage 3 (documented AF), and Stage 4 (permanent AF).
  • •Hypertension is the most prevalent modifiable risk factor, with a population-attributable fraction of ~20%. Obesity (each 5 kg/m² BMI increase raises risk 1.3-1.5-fold), obstructive sleep apnea, diabetes, heart failure, chronic kidney disease, alcohol (heavy consumption), and physical inactivity are established drivers. Age is the strongest non-modifiable risk factor, hazard doubles each decade after age 50.

Evaluation

  • •Suspect AF in any patient presenting with palpitations (sudden onset of rapid, irregular, or fluttering heartbeat), dyspnea, exertional intolerance, fatigue, dizziness, presyncope, or syncope. Up to 40% of patients are asymptomatic, discovered incidentally on routine examination or after a thromboembolic event.
  • •The classic physical finding is an irregularly irregular pulse with variable pulse amplitude. S1 heart sound varies in intensity, and the jugular venous pulse loses normally occurring a-waves. Always examine for signs of heart failure (elevated JVP, pulmonary crackles, peripheral edema), hyperthyroidism, obesity, and sleep apnea (crowded oropharynx, large neck circumference).
  • •Gold-standard diagnosis is a 12-lead ECG showing absolute R-R interval irregularity, absence of discrete P waves with fibrillatory waves, and narrow QRS (unless pre-existing conduction disease). Arrhythmia must persist ≥30 seconds for the diagnosis of clinical AF.
  • •If paroxysmal AF is suspected but the initial ECG is non-diagnostic, proceed to ambulatory monitoring: a 24-hour Holter for frequent symptoms, 7-day patch monitor for higher yield, or 30-day event recorder/insertable cardiac monitor (ICM) for infrequent episodes. After cryptogenic stroke, ICM detects AF at 6 times the rate of conventional follow-up within 6 months.
  • •Order laboratory studies in all new AF: thyroid function (TSH), electrolytes (K+, Mg), renal function, complete blood count, and natriuretic peptides (BNP/NT-proBNP). Consider toxicology screen if alcohol or stimulant use is suspected.
  • •Transthoracic echocardiography is indicated for all patients to assess left atrial size (volume index ≥34 mL/m² correlates with AF persistence), left ventricular systolic and diastolic function, valvular disease, and pericardial pathology.
  • •Transesophageal echocardiography (TEE) is reserved before cardioversion or catheter ablation if anticoagulation has not been therapeutic for ≥3 weeks. Intracardiac echocardiography (ICE) is a growing alternative with noninferior safety and less major bleeding from transseptal puncture.
  • •Diagnostic criteria require ECG documentation of ≥30 seconds of AF. The workup should confirm the arrhythmia, characterize its pattern (first-detected, paroxysmal, persistent, long-standing persistent), identify precipitants (thyroid, alcohol, surgery, infection, MI, pericarditis), assess structural substrate, and evaluate for concomitant conditions (hypertension, sleep apnea, obesity, diabetes, CAD, heart failure).
  • •Use the EHRA score to grade symptom burden: Class I (asymptomatic) through Class IV (disabling). Remember that symptom absence does not predict low thromboembolic risk, silent AF carries stroke risk comparable to symptomatic paroxysms.

Management

  • •First, assess hemodynamic stability. If unstable (hypotension, acute myocardial ischemia, pulmonary edema, altered mental status due to rapid ventricular response), proceed urgently to synchronized electrical cardioversion starting at 100-200 J biphasic.
  • •For hemodynamically stable patients, decide between rate control and rhythm control based on symptom burden, AF duration, and comorbidities. Early rhythm control within one year of diagnosis reduces cardiovascular events (HR 0.79, NNT = 37 at 5 years).
  • •Acute rate control: beta-blockers ( 5 mg IV every 5 min ×3 doses, then 25-50 mg PO BID; target 200 mg daily) or nondihydropyridine calcium channel blockers ( 0.25 mg/kg IV, then 5-15 mg/h infusion; max 360 mg PO daily) are first-line. Avoid diltiazem if LVEF <40%.
  • •For rate control in HFpEF or permanent AF with HF symptoms, consider 0.0625-0.125 mg PO daily (target serum level 0.5-0.9 ng/mL). RATE-AF trial showed superior symptom improvement versus in this population.
  • •Heart rate target for rate control: <80 bpm at rest (class IIa) or <110 bpm with moderate exertion (class IIb). Beta-blockers do not reduce mortality in patients with concomitant HF and AF (HR 0.97).
  • •For pharmacologic cardioversion without structural heart disease: 2 mg/kg IV or 300 mg PO, or 2 mg/kg IV or 600 mg PO. For structural heart disease: 1.2-1.8 g PO in divided doses over 24 hours.
  • •Electrical cardioversion with biphasic synchronized shock (100-150 J initial) requires therapeutic anticoagulation for ≥3 weeks or a TEE excluding left atrial appendage thrombus.
  • •Initiate oral anticoagulation based on CHA₂DS₂-VASc score: recommend DOAC for men with score ≥2 and women with score ≥3. Direct oral anticoagulants are preferred over warfarin: 5 mg BID (reduce to 2.5 mg BID if age ≥80 years, weight ≤60 kg, or creatinine ≥1.5 mg/dL); 20 mg daily with food (15 mg if CrCl 15-49); 60 mg daily (30 mg if weight ≤60 kg, CrCl 15-49, or P-gp inhibitor).
  • •After acute ischemic stroke with AF, initiate a DOAC early (≤4 days) to reduce recurrent ischemic stroke without increasing intracranial hemorrhage (CATALYST meta-analysis OR 0.70, NNT = 111).
  • •For patients with AF and stable CAD, use OAC monotherapy (DOAC alone), the EPIC-CAD trial showed 56% relative risk reduction in composite outcomes versus dual antithrombotic therapy (NNT = 12).
  • •Do NOT use for stroke prevention in AF, it is inferior to OAC and carries similar bleeding risk. Avoid non-dihydropyridine CCBs (verapamil, diltiazem) in HFrEF. Avoid as first-line for pharmacologic cardioversion without structural heart disease.
  • •Risk factor modification is essential: target ≥10% weight loss in obese patients (reduces AF recurrence after ablation by nearly half), blood pressure <130/80 mm Hg, screen for and treat obstructive sleep apnea, and recommend alcohol abstinence (reduces recurrence HR 0.55).
  • •Refer for catheter ablation (pulmonary vein isolation) as first-line therapy for symptomatic paroxysmal AF and for selected persistent AF patients. In HFrEF, ablation improves survival and reduces HF hospitalizations (CASTLE-AF: NNT = 7 for primary outcome).
  • •Continue anticoagulation indefinitely after successful ablation if CHA₂DS₂-VASc ≥2 (men) or ≥3 (women), regardless of rhythm success. Discontinuation may be considered only after shared decision-making in lower-risk patients.
  • •Left atrial appendage occlusion is a reasonable alternative for stroke prevention in patients with clear contraindications to long-term anticoagulation.
  • •AV junction ablation with biventricular pacing (CRT) is a rescue strategy for patients with refractory rapid ventricular rates despite maximal medical therapy, APAF-CRT showed reduced mortality versus pharmacologic rate control (NNT = 6 at 2 years).

Board Review — High Yield

  • •CHA₂DS₂-VASc, Most validated stroke risk score; initiate OAC for men ≥2, women ≥3; includes age ≥75 (2 pts), age 65-74 (1 pt), female sex (1 pt), vascular disease, diabetes, hypertension, HF.
  • •EAST-AFNET 4, Early rhythm control within 1 year of AF diagnosis reduces CV death, stroke, HF hospitalization, or ACS (HR 0.79); NNT = 37 at 5 years.
  • •CASTLE-AF, Catheter ablation in HFrEF with AF reduces all-cause mortality (13.4% vs 25.0%) and HF hospitalization; NNT = 7 for primary outcome.
  • •RATE-AF, In permanent AF with HFpEF, digoxin improved symptoms and NYHA class versus bisoprolol with fewer adverse events; NNT = 2 to improve one NYHA class.
  • •Apixaban vs warfarin, ARISTOTLE: apixaban reduces stroke/SE (HR 0.79) and major bleeding (HR 0.69); NNT 303/yr for stroke prevention.
  • •ALONE-AF, Discontinuing OAC after successful ablation in lower-risk patients (mean CHA₂DS₂-VASc ~2) reduced major bleeding without increasing stroke; shared decision-making required.
  • •DOAC meta-analysis (COMBINE AF), Standard-dose DOACs reduce stroke/SE 19%, all-cause mortality 8%, intracranial hemorrhage 55% vs warfarin.
  • •Subclinical AF, Device-detected AF lasting 6 min-24 h carries 2.5-fold increased stroke risk; anticoagulation provides net benefit only in higher-risk patients (CHA₂DS₂-VASc ≥4).
  • •Lifestyle modification, ≥10% weight loss after ablation reduces recurrence by 47% (ARREST-AF); alcohol abstinence reduces recurrence by 45%.
  • •Pulsed field ablation, Newer nonthermal energy noninferior to cryoballoon with lower procedural complication rates; caution for coronary vasospasm near arteries.

Deep Dive — Evidence Details

References

  1. [1]

    Joglar JA, Chung MK, Armbruster AL et al.. “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2023). PMID: 38033089 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  2. [2]

    Heidenreich PA, Bozkurt B, Aguilar D et al.. “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2022). PMID: 35363499 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Special Populations and Prevention
  3. [3]

    Rao SV, O'Donoghue ML, Ruel M et al.. “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2025). PMID: 40014670 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  4. [4]

    Ommen SR, Ho CY, Asif IM et al.. “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.” Circulation (2024). PMID: 38718139 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Special Populations and Prevention
  5. [5]

    Heidenreich PA, Bozkurt B, Aguilar D et al.. “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2022). PMID: 35363500 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Long-term Guideline-Directed Therapy, Special Populations and Prevention
  6. [6]

    Wigginton JG, Agarwal S, Bartos JA et al.. “Part 9: Adult Advanced Life Support: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.” Circulation (2025). PMID: 41122884 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
  7. [7]

    Arnett DK, Blumenthal RS, Albert MA et al.. “2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.” Circulation (2019). PMID: 30879339 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  8. [8]

    Ndumele CE, Rodriguez F, Dixon DL et al.. “2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2026). PMID: 42263157 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Long-term Guideline-Directed Therapy
  9. [9]

    Heidenreich PA, Bozkurt B, Aguilar D et al.. “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2022). PMID: 35379503 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Special Populations and Prevention
  10. [10]

    Rao SV, O'Donoghue ML, Ruel M et al.. “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2025). PMID: 40013746 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  11. [11]

    Joglar JA, Chung MK, Armbruster AL et al.. “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2023). PMID: 38043043 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  12. [12]

    Kittleson MM, Ambardekar AV, Cheng RK et al.. “Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.” Journal of the American College of Cardiology (2025). PMID: 41171219 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy, History and Evolution of Treatment
  13. [13]

    Osmancik P, Herman D, Neuzil P et al.. “Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.” Journal of the American College of Cardiology (2020). PMID: 32586585 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History
  14. [14]

    Reddy VY, Doshi SK, Kar S et al.. “5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.” Journal of the American College of Cardiology (2017). PMID: 29103847 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment
  15. [15]

    van Veldhuisen SL, Gorter TM, van Woerden G et al.. “Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.” European heart journal (2022). PMID: 35243488 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Complications, Prognosis and Natural History
  16. [16]

    Willems S, Borof K, Brandes A et al.. “Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial.” European heart journal (2022). PMID: 34447995 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention
  17. [17]

    Hohnloser SH, Camm J, Cappato R et al.. “Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.” European heart journal (2019). PMID: 30976787 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment
  18. [18]

    Davidson KW, Barry MJ, Mangione CM et al.. “Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement.” JAMA (2022). PMID: 35076659 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation
  19. [19]

    Yndigegn T, Lindahl B, Mars K et al.. “Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.” The New England journal of medicine (2024). PMID: 38587241 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Populations and Prevention
  20. [20]

    Healey JS, Lopes RD, Granger CB et al.. “Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.” The New England journal of medicine (2023). PMID: 37952132 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  21. [21]

    Ruff CT, Patel SM, Giugliano RP et al.. “Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.” The New England journal of medicine (2025). PMID: 39842011 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification
  22. [22]

    Connolly SJ, Karthikeyan G, Ntsekhe M et al.. “Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.” The New England journal of medicine (2022). PMID: 36036525 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  23. [23]

    Lee SJ, Yu HT, Lee YJ et al.. “Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.” The New England journal of medicine (2025). PMID: 41211917 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Interventional and Device Therapy
  24. [24]

    Sohns C, Fox H, Marrouche NF et al.. “Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation.” The New England journal of medicine (2023). PMID: 37634135 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Interventional and Device Therapy
  25. [25]

    Lindholt JS, Søgaard R, Rasmussen LM et al.. “Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial.” The New England journal of medicine (2022). PMID: 36027560 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  26. [26]

    Leon MB, Smith CR, Mack MJ et al.. “Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.” The New England journal of medicine (2016). PMID: 27040324 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  27. [27]

    Shoureshi P, Tan AY, Koneru J et al.. “Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2024). PMID: 38811098 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup
  28. [28]

    Rossi GP. “Primary Aldosteronism: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2019). PMID: 31779795 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Complications
  29. [29]

    Werring DJ, Dehbi HM, Ahmed N et al.. “Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial.” Lancet (London, England) (2024). PMID: 39491870 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  30. [30]

    Svendsen JH, Diederichsen SZ, Højberg S et al.. “Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial.” Lancet (London, England) (2021). PMID: 34469766 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  31. [31]

    Svennberg E, Friberg L, Frykman V et al.. “Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial.” Lancet (London, England) (2021). PMID: 34469764 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment
  32. [32]

    Oraii A, McIntyre WF, Parkash R et al.. “Atrial Fibrillation Ablation in Heart Failure With Reduced vs Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.” JAMA cardiology (2024). PMID: 38656292 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Prognosis and Natural History
  33. [33]

    Kahwati LC, Asher GN, Kadro ZO et al.. “Screening for Atrial Fibrillation: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2022). PMID: 35076660 ↗

    L2SR_OBSCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  34. [34]

    Jonas DE, Kahwati LC, Yun JDY et al.. “Screening for Atrial Fibrillation With Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2018). PMID: 30088015 ↗

    L2SR_OBSCited in: Definition, Classification and Nomenclature
  35. [35]

    Attia ZI, Harmon DM, Behr ER et al.. “Application of artificial intelligence to the electrocardiogram.” European heart journal (2021). PMID: 34534279 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  36. [36]

    Kany S, Jurgens SJ, Rämö JT et al.. “Genetic testing in early-onset atrial fibrillation.” European heart journal (2024). PMID: 39028637 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
  37. [37]

    Svennberg E, Freedman B, Andrade JG et al.. “Recent-onset atrial fibrillation: challenges and opportunities.” European heart journal (2026). PMID: 40873195 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  38. [38]

    Lu Y, Sun Y, Cai L et al.. “Non-traditional risk factors for atrial fibrillation: epidemiology, mechanisms, and strategies.” European heart journal (2025). PMID: 39716283 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Diagnosis and Workup, History and Evolution of Treatment, Special Populations and Prevention
  39. [39]

    Gladstone DJ, Wachter R, Schmalstieg-Bahr K et al.. “Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial.” JAMA cardiology (2021). PMID: 33625468 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  40. [40]

    Pathak RK, Elliott AD, Lau DH et al.. “Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 41160038 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  41. [41]

    Hu X, Jiang W, Wang X et al.. “Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 41060665 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  42. [42]

    Sang C, Liu Q, Lai Y et al.. “Pulmonary Vein Isolation With Optimized Linear Ablation vs Pulmonary Vein Isolation Alone for Persistent AF: The PROMPT-AF Randomized Clinical Trial.” JAMA (2025). PMID: 39556379 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  43. [43]

    Wijesurendra R, Pessoa-Amorim G, Buck G et al.. “Remote Screening for Asymptomatic Atrial Fibrillation: The AMALFI Randomized Clinical Trial.” JAMA (2025). PMID: 40878848 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment
  44. [44]

    Marrouche NF, Wazni O, McGann C et al.. “Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial.” JAMA (2022). PMID: 35727277 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy, Prognosis and Natural History
  45. [45]

    Kosiborod MN, Cherney D, Connelly K et al.. “Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline Characteristics.” JACC. Heart failure (2024). PMID: 38878009 ↗

    L5RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  46. [46]

    Cohen JB, Schrauben SJ, Zhao L et al.. “Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.” JACC. Heart failure (2020). PMID: 31926856 ↗

    L2RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
  47. [47]

    Litwin SE, Komtebedde J, Hu M et al.. “Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction.” JACC. Heart failure (2023). PMID: 36939661 ↗

    L2RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  48. [48]

    Noseworthy PA, Attia ZI, Behnken EM et al.. “Artificial intelligence-guided screening for atrial fibrillation using electrocardiogram during sinus rhythm: a prospective non-randomised interventional trial.” Lancet (London, England) (2022). PMID: 36179758 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  49. [49]

    Kondo T, Jering KS, Jhund PS et al.. “Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation.” Circulation. Heart failure (2023). PMID: 37350280 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  50. [50]

    Zylla MM, Leiner J, Rahm AK et al.. “Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure and Preserved Ejection Fraction.” Circulation. Heart failure (2022). PMID: 36126143 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Prognosis and Natural History
  51. [51]

    MacGowan H, Brown OI, Drozd M et al.. “Comorbidity trajectories before and after the diagnosis of heart failure: A UK Biobank cohort study.” European journal of heart failure (2025). PMID: 39935109 ↗

    L2COHORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup
  52. [52]

    Grams ME, Coresh J, Matsushita K et al.. “Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.” JAMA (2023). PMID: 37787795 ↗

    L2SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications, Special Populations and Prevention
  53. [53]

    Campbell BCV, Khatri P. “Stroke.” Lancet (London, England) (2020). PMID: 32653056 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  54. [54]

    Lane DA, Andrade JG, Arbelo E et al.. “Atrial fibrillation.” Lancet (London, England) (2026). PMID: 41794418 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  55. [55]

    Maron BJ, Maron MS. “Hypertrophic cardiomyopathy.” Lancet (London, England) (2012). PMID: 22874472 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Special Populations and Prevention
  56. [56]

    Hankey GJ. “Stroke.” Lancet (London, England) (2016). PMID: 27637676 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Special Populations and Prevention
  57. [57]

    Mueller C, McDonald K, de Boer RA et al.. “Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations.” European journal of heart failure (2019). PMID: 31222929 ↗

    L1REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management
  58. [58]

    Meder B, Coats CJ, Leinwand LA et al.. “EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathy.” European journal of heart failure (2026). PMID: 41771101 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Special Populations and Prevention
  59. [59]

    Nagueh SF. “Non-invasive assessment of left ventricular filling pressure.” European journal of heart failure (2017). PMID: 28990316 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  60. [60]

    Ferrari R, Böhm M, Cleland JG et al.. “Heart failure with preserved ejection fraction: uncertainties and dilemmas.” European journal of heart failure (2015). PMID: 26079097 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, History and Evolution of Treatment, Prognosis and Natural History
  61. [61]

    Pieske B, Tschöpe C, de Boer RA et al.. “How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).” European heart journal (2019). PMID: 31504452 ↗

    L1OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  62. [62]

    Anand V, Bonow RO, Nishimura RA et al.. “Myocardial Dysfunction in Primary Mitral Regurgitation: A Review.” JAMA cardiology (2026). PMID: 41405892 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  63. [63]

    Ko D, Chung MK, Evans PT et al.. “Atrial Fibrillation: A Review.” JAMA (2025). PMID: 39680399 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  64. [64]

    Milwidsky A, Mathai SV, Topilsky Y et al.. “Medical Therapy for Functional Mitral Regurgitation.” Circulation. Heart failure (2022). PMID: 35862021 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  65. [65]

    Desai MY, Maurizi N, Biagini E et al.. “Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy.” JACC. Heart failure (2025). PMID: 40997544 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History
  66. [66]

    Braunwald E. “Heart failure.” JACC. Heart failure (2013). PMID: 24621794 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
  67. [67]

    Carlisle MA, Fudim M, DeVore AD et al.. “Heart Failure and Atrial Fibrillation, Like Fire and Fury.” JACC. Heart failure (2019). PMID: 31146871 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  68. [68]

    Zeitler EP, Johnson AE, Cooper LB et al.. “Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction: New Assessment of an Old Problem.” JACC. Heart failure (2024). PMID: 39152985 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy, Complications
  69. [69]

    Reddy YNV, Noseworthy P, Borlaug BA et al.. “Screening for Unrecognized HFpEF in Atrial Fibrillation and for Unrecognized Atrial Fibrillation in HFpEF.” JACC. Heart failure (2024). PMID: 38839160 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  70. [70]

    Li S, Sun Y, Lai Y et al.. “Heart Failure Medication Withdrawal in Patients With Improved Cardiac Function After Atrial Fibrillation Ablation: The DEFINITION-AF Pilot Randomized Clinical Trial.” JAMA network open (2026). PMID: 42360743 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, History and Evolution of Treatment, Complications
  71. [71]

    Roten L, Kueffer T, Badertscher P et al.. “Autonomic effects and ablation success after pulsed field and cryoballoon ablation: a SINGLE SHOT CHAMPION substudy.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026). PMID: 42300255 ↗

    L1RCTCited in: Definition, Classification and Nomenclature
  72. [72]

    Ozaki T, Inoue K, Mishima T et al.. “Impact of Diabetes on the Efficacy of Low-Voltage Area Ablation for Persistent Atrial Fibrillation: A Subanalysis of the SUPPRESS-AF Trial.” Journal of the American Heart Association (2026). PMID: 42294760 ↗

    L2RCTCited in: Definition, Classification and Nomenclature
  73. [73]

    Deng C, Xu Y, Adilijiang A et al.. “Comparative Effectiveness and Safety of Interventions for Atrial Fibrillation in Heart Failure: A Network Meta-Analysis of Randomized Trials.” Cardiovascular therapeutics (2026). PMID: 42411564 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
  74. [74]

    Clapham RE, Speed V, Cox C et al.. “Identifying risk factors for venous thromboembolism in medical inpatients: a systematic review and meta-analysis.” Research and practice in thrombosis and haemostasis (2026). PMID: 42318434 ↗

    L2SR_OBSCited in: Definition, Classification and Nomenclature, Clinical Presentation, Severity Staging and Risk Stratification, History and Evolution of Treatment
  75. [75]

    Hashiba M, Linz D, Frandsen R et al.. “VIR-SAAF: a study protocol for a national decentralised randomised controlled trial of home-based sleep apnoea screening in patients with atrial fibrillation in Denmark.” BMJ open (2026). PMID: 42409410 ↗

    L5TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
  76. [76]

    Oliva RV, Magno JDA, David-Ona DI et al.. “Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Cardiovascular Disease.” Acta medica Philippina (2026). PMID: 42382937 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Long-term Guideline-Directed Therapy
  77. [77]

    Weerts J, Țica O, Aranyo J et al.. “Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC.” European journal of heart failure (2025). PMID: 40763073 ↗

    L1OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Complications
  78. [78]

    Rosano GMC, Moura B, Metra M et al.. “Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology.” European journal of heart failure (2021). PMID: 33932268 ↗

    L1OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy
  79. [79]

    Pieske B, Tschöpe C, de Boer RA et al.. “How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).” European journal of heart failure (2020). PMID: 32133741 ↗

    L1OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  80. [80]

    Kanniyan AS, Mohammed O, Wadhwa A et al.. “Intracardiac Echocardiography Versus Transesophageal Echocardiography for Guidance of Atrial Fibrillation Ablation: A Systematic Review and Meta-Analysis of Procedural Safety and Efficacy.” Echocardiography (Mount Kisco, N.Y.) (2026). PMID: 42390195 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  81. [81]

    Rämö JT, Kany S, Hou CR et al.. “Cardiovascular Significance and Genetics of Epicardial and Pericardial Adiposity.” JAMA cardiology (2024). PMID: 38477908 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup
  82. [82]

    Karim S, Chahal A, Venkataraman S et al.. “Prevalence and Clinical Implications of Sleep Apnea in Hypertrophic Cardiomyopathy.” JAMA cardiology (2025). PMID: 40900558 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  83. [83]

    Ajufo E, Kany S, Jurgens SJ et al.. “Physical Activity and Cardiovascular Outcomes in Phenotype-Negative Cardiomyopathy Variant Carriers.” JAMA cardiology (2026). PMID: 41205222 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature
  84. [84]

    Akhtar MM, Lorenzini M, Cicerchia M et al.. “Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene.” Circulation. Heart failure (2020). PMID: 32964742 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Prognosis and Natural History
  85. [85]

    Tahir UA, Kolm P, Kwong RY et al.. “Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy.” Circulation. Heart failure (2024). PMID: 39498543 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Complications
  86. [86]

    Azzo JD, Dib MJ, Zagkos L et al.. “Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction.” Circulation. Heart failure (2024). PMID: 38299345 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  87. [87]

    Buckley LF, Agha AM, Dorbala P et al.. “MMP-2 Associates With Incident Heart Failure and Atrial Fibrillation: The ARIC Study.” Circulation. Heart failure (2023). PMID: 37753653 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Complications
  88. [88]

    Reddy YNV, Frantz RP, Hassoun PM et al.. “Left Heart Abnormalities in Patients With Lung Disease, OSA, and Chronic Thromboemboli at Risk for or With Known Pulmonary Hypertension.” Circulation. Heart failure (2025). PMID: 40438933 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Complications
  89. [89]

    Carnicelli AP, Hong H, Connolly SJ et al.. “Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.” Circulation (2022). PMID: 34985309 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  90. [90]

    Maron BJ, Desai MY, Nishimura RA et al.. “Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2022). PMID: 35086661 ↗

    L5SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  91. [91]

    Pokorney SD, Chertow GM, Al-Khalidi HR et al.. “Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.” Circulation (2022). PMID: 36335914 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Populations and Prevention
  92. [92]

    Gawałko M, Middeldorp ME, Saljic A et al.. “Diet and risk of atrial fibrillation: a systematic review.” European heart journal (2024). PMID: 39288159 ↗

    L5SR_OBSCited in: Epidemiology and Risk Factors
  93. [93]

    Kim MS, Kim WJ, Khera AV et al.. “Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies.” European heart journal (2021). PMID: 34333589 ↗

    L2SR_OBSCited in: Epidemiology and Risk Factors, Clinical Presentation, Complications
  94. [94]

    Jørgensen TH, Thyregod HGH, Savontaus M et al.. “Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis: the NOTION-2 trial.” European heart journal (2024). PMID: 38747246 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  95. [95]

    Khan MS, Samman Tahhan A, Vaduganathan M et al.. “Trends in prevalence of comorbidities in heart failure clinical trials.” European journal of heart failure (2020). PMID: 32293090 ↗

    L2TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors
  96. [96]

    Bhatt DL, Steg PG, Miller M et al.. “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.” The New England journal of medicine (2018). PMID: 30415628 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention
  97. [97]

    Fischer U, Koga M, Strbian D et al.. “Early versus Later Anticoagulation for Stroke with Atrial Fibrillation.” The New England journal of medicine (2023). PMID: 37222476 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  98. [98]

    Patel MR, Mahaffey KW, Garg J et al.. “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.” The New England journal of medicine (2011). PMID: 21830957 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  99. [99]

    Marty FM, Ljungman P, Chemaly RF et al.. “Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.” The New England journal of medicine (2017). PMID: 29211658 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  100. [100]

    Lincoff AM, Bhasin S, Flevaris P et al.. “Cardiovascular Safety of Testosterone-Replacement Therapy.” The New England journal of medicine (2023). PMID: 37326322 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  101. [101]

    Cho MS, Kang DY, Ahn JM et al.. “Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.” The New England journal of medicine (2024). PMID: 39225258 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  102. [102]

    Kirchhof P, Camm AJ, Goette A et al.. “Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.” The New England journal of medicine (2020). PMID: 32865375 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Populations and Prevention
  103. [103]

    Landmesser U, Skurk C, Kirchhof P et al.. “Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation.” The New England journal of medicine (2026). PMID: 41849741 ↗

    L1RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment, Complications, Prognosis and Natural History
  104. [104]

    Kotecha D, Holmes J, Krum H et al.. “Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.” Lancet (London, England) (2014). PMID: 25193873 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  105. [105]

    Powell-Wiley TM, Poirier P, Burke LE et al.. “Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association.” Circulation (2021). PMID: 33882682 ↗

    L1REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Complications
  106. [106]

    Yeghiazarians Y, Jneid H, Tietjens JR et al.. “Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association.” Circulation (2021). PMID: 34148375 ↗

    L1REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Interventional and Device Therapy, Complications
  107. [107]

    Iwasaki YK, Nishida K, Kato T et al.. “Atrial fibrillation pathophysiology: implications for management.” Circulation (2011). PMID: 22083148 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy, Special Populations and Prevention
  108. [108]

    Tisdale JE, Chung MK, Campbell KB et al.. “Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association.” Circulation (2020). PMID: 32929996 ↗

    L1REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management
  109. [109]

    Chyou JY, Barkoudah E, Dukes JW et al.. “Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association.” Circulation (2023). PMID: 36912134 ↗

    L1REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  110. [110]

    Joynt Maddox KE, Elkind MSV, Aparicio HJ et al.. “Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050-Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association.” Circulation (2024). PMID: 38832505 ↗

    L1REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Complications
  111. [111]

    Diener HC, Hankey GJ. “Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar.” Journal of the American College of Cardiology (2020). PMID: 32299593 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Complications, Special Populations and Prevention
  112. [112]

    Ricci F, De Caterina R, Fedorowski A. “Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment.” Journal of the American College of Cardiology (2015). PMID: 26271068 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
  113. [113]

    Volgman AS, Nair G, Lyubarova R et al.. “Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2022). PMID: 35027110 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Clinical Presentation, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Special Populations and Prevention
  114. [114]

    Javaheri S, Javaheri S, Somers VK et al.. “Interactions of Obstructive Sleep Apnea With the Pathophysiology of Cardiovascular Disease, Part 1: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2024). PMID: 39293884 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism
  115. [115]

    Deferm S, Bertrand PB, Verbrugge FH et al.. “Atrial Functional Mitral Regurgitation: JACC Review Topic of the Week.” Journal of the American College of Cardiology (2019). PMID: 31097168 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management
  116. [116]

    Cowie MR, Linz D, Redline S et al.. “Sleep Disordered Breathing and Cardiovascular Disease: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2021). PMID: 34353537 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
  117. [117]

    Lavie CJ, Milani RV, Ventura HO. “Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss.” Journal of the American College of Cardiology (2009). PMID: 19460605 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification
  118. [118]

    Haimovich JS, Kany S, Ajufo E et al.. “Outcomes and Management of Stressor-Associated Atrial Fibrillation: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2025). PMID: 40962378 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy
  119. [119]

    Turan A, Duncan A, Leung S et al.. “Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial.” Lancet (London, England) (2020). PMID: 32682483 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  120. [120]

    Holmes DR, Reddy VY, Turi ZG et al.. “Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.” Lancet (London, England) (2009). PMID: 19683639 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, History and Evolution of Treatment, Complications
  121. [121]

    Piccini JP, Caso V, Connolly SJ et al.. “Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.” Lancet (London, England) (2022). PMID: 35385695 ↗

    L1RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment, Complications
  122. [122]

    Dhont S, Bertrand PB, Erzeel J et al.. “The interaction between atrial fibrillation and mitral regurgitation: Insights from the CABANA randomized clinical trial.” European journal of heart failure (2025). PMID: 40256860 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  123. [123]

    Lin AY, Dinatolo E, Metra M et al.. “Thromboembolism in Heart Failure Patients in Sinus Rhythm: Epidemiology, Pathophysiology, Clinical Trials, and Future Direction.” JACC. Heart failure (2021). PMID: 33714744 ↗

    L5TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors
  124. [124]

    Reichlin T, Kueffer T, Badertscher P et al.. “Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation.” The New England journal of medicine (2025). PMID: 40162734 ↗

    L1TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  125. [125]

    Gaudino M, Di Franco A, Rong LQ et al.. “Postoperative atrial fibrillation: from mechanisms to treatment.” European heart journal (2023). PMID: 36721960 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  126. [126]

    Kelters IR, Koop Y, Young ME et al.. “Circadian rhythms in cardiovascular disease.” European heart journal (2025). PMID: 40663373 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  127. [127]

    Lauder L, Mahfoud F, Azizi M et al.. “Hypertension management in patients with cardiovascular comorbidities.” European heart journal (2023). PMID: 36342266 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  128. [128]

    Natale A, Mohanty S, Sanders P et al.. “Catheter ablation for atrial fibrillation: indications and future perspective.” European heart journal (2024). PMID: 39322413 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  129. [129]

    Zimerman A, Braunwald E, Steffel J et al.. “Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.” JAMA cardiology (2024). PMID: 38985461 ↗

    L2RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  130. [130]

    Alexander JH, Lydon EJ, Piccini JP et al.. “Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 40136309 ↗

    L2RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  131. [131]

    Wong CX, Cheung CC, Montenegro G et al.. “Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial.” JAMA (2026). PMID: 41206802 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Special Populations and Prevention
  132. [132]

    Packer DL, Mark DB, Robb RA et al.. “Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.” JAMA (2019). PMID: 30874766 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  133. [133]

    Tromp J, Claggett BL, Liu J et al.. “Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.” Circulation. Heart failure (2021). PMID: 33866828 ↗

    L2RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment
  134. [134]

    McMurray JJV, Wheeler DC, Stefánsson BV et al.. “Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.” JACC. Heart failure (2021). PMID: 34446370 ↗

    L2RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Populations and Prevention
  135. [135]

    Kondo T, Campbell R, Jhund PS et al.. “Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.” JACC. Heart failure (2024). PMID: 38904646 ↗

    L2RCTCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
  136. [136]

    van Veldhuisen DJ, Rienstra M, Mosterd A et al.. “Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial.” European journal of heart failure (2024). PMID: 39212246 ↗

    L5TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  137. [137]

    Lund LH, James S, DeVore AD et al.. “The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design.” European journal of heart failure (2024). PMID: 39282788 ↗

    L5TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  138. [138]

    Kim D, Shim J, Choi EK et al.. “Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial.” JAMA (2025). PMID: 40886309 ↗

    L1TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  139. [139]

    Nayak SS, Amini-Salehi E, Letafatkar N et al.. “Clinical outcomes of continuing vs. discontinuing oral anticoagulation after atrial fibrillation ablation: an updated systematic review and meta-analysis of observational studies and randomized controlled trials.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026). PMID: 42414231 ↗

    L2SR_MA_RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  140. [140]

    Schnabel RB, Yin X, Gona P et al.. “50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study.” Lancet (London, England) (2015). PMID: 25960110 ↗

    L2COHORTCited in: Epidemiology and Risk Factors
  141. [141]

    Rawshani A, Sattar N, Franzén S et al.. “Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.” Lancet (London, England) (2018). PMID: 30129464 ↗

    L2COHORTCited in: Epidemiology and Risk Factors
  142. [142]

    Bielecka-Dabrowa A, Ebner N, Dos Santos MR et al.. “Cachexia, muscle wasting, and frailty in cardiovascular disease.” European journal of heart failure (2020). PMID: 32949422 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Special Populations and Prevention
  143. [143]

    Triposkiadis F, Giamouzis G, Parissis J et al.. “Reframing the association and significance of co-morbidities in heart failure.” European journal of heart failure (2016). PMID: 27358242 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Prognosis and Natural History, Special Populations and Prevention
  144. [144]

    Wang J, Huang P, Yu Q et al.. “Epilepsy and long-term risk of arrhythmias.” European heart journal (2023). PMID: 37602368 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  145. [145]

    Linz D, McEvoy RD, Cowie MR et al.. “Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment: A Review.” JAMA cardiology (2018). PMID: 29541763 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications
  146. [146]

    Redfield MM, Borlaug BA. “Heart Failure With Preserved Ejection Fraction: A Review.” JAMA (2023). PMID: 36917048 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Complications, Prognosis and Natural History
  147. [147]

    Ruberg FL, Maurer MS. “Cardiac Amyloidosis Due to Transthyretin Protein: A Review.” JAMA (2024). PMID: 38441582 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Complications, Prognosis and Natural History
  148. [148]

    Douketis JD, Spyropoulos AC. “Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review.” JAMA (2024). PMID: 39133476 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  149. [149]

    Chaker L, Papaleontiou M. “Hypothyroidism: A Review.” JAMA (2025). PMID: 40900603 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Special Populations and Prevention
  150. [150]

    Packer M. “HFpEF Is the Substrate for Stroke in Obesity and Diabetes Independent of Atrial Fibrillation.” JACC. Heart failure (2019). PMID: 31706838 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
  151. [151]

    Elshahat A, Diaa A, Diab RA et al.. “Effectiveness and safety of left atrial appendage electrical isolation in managing persistent atrial fibrillation: an updated meta-analysis of 3425 patients.” BMC cardiovascular disorders (2026). PMID: 42426602 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors, Interventional and Device Therapy
  152. [152]

    Shen T, Shi C, Li G et al.. “Effects of cardiac rehabilitation on atrial fibrillation recurrence, mortality, hospitalization, and exercise capacity: a systematic review and meta-analysis.” PeerJ (2026). PMID: 42376039 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Prognosis and Natural History
  153. [153]

    Kaisaier W, Chen Y, Dong Y et al.. “Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.” Thrombosis and haemostasis (2026). PMID: 42398953 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors, Interventional and Device Therapy
  154. [154]

    Chioncel O, Lainscak M, Seferovic PM et al.. “Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.” European journal of heart failure (2017). PMID: 28386917 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy
  155. [155]

    Matsumoto S, Henderson AD, Shen L et al.. “Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction.” European journal of heart failure (2024). PMID: 39215677 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
  156. [156]

    Vilches S, Fontana M, Gonzalez-Lopez E et al.. “Systemic embolism in amyloid transthyretin cardiomyopathy.” European journal of heart failure (2022). PMID: 35650018 ↗

    L3OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications, Prognosis and Natural History
  157. [157]

    Wu H, Zhou Z, Huang L et al.. “Association and predictive value of preoperative high-sensitivity C-reactive protein for postoperative atrial fibrillation after video-assisted thoracoscopic lobectomy: a cohort study using the INSPIRE database.” BMC anesthesiology (2026). PMID: 42420856 ↗

    L3COHORTCited in: Epidemiology and Risk Factors
  158. [158]

    Niu X, Tang X, Fang X et al.. “Left Atrial Appendage Closure With Different Antithrombotic Therapies in Patients at High Bleeding Risk: A Ten-Year Cohort Study.” The Canadian journal of cardiology (2026). PMID: 42413819 ↗

    L3COHORTCited in: Epidemiology and Risk Factors, Complications, Prognosis and Natural History
  159. [159]

    Dong H, Han C, Chen Y et al.. “Accelerometer-measured physical activity fragmentation and incident cardiovascular diseases: a prospective cohort study.” Nutrition journal (2026). PMID: 42402585 ↗

    L2COHORTCited in: Epidemiology and Risk Factors, Prognosis and Natural History
  160. [160]

    Ryan D, Yahav A, Barnett-Griness O et al.. “Trends in stroke risk among female and male patients with atrial fibrillation: a 20-year population-based cohort study.” Heart rhythm (2026). PMID: 42379411 ↗

    L3COHORTCited in: Epidemiology and Risk Factors
  161. [161]

    Stender BS, Eskildsen VK, Kramer A et al.. “Compliance to direct oral anticoagulation therapy and clinical outcomes after catheter ablation for atrial fibrillation: a nationwide cohort study.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026). PMID: 42378507 ↗

    L3COHORTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Complications
  162. [162]

    Said MA, Verweij N, van der Harst P. “Associations of Combined Genetic and Lifestyle Risks With Incident Cardiovascular Disease and Diabetes in the UK Biobank Study.” JAMA cardiology (2018). PMID: 29955826 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Prognosis and Natural History
  163. [163]

    Yoneda ZT, Anderson KC, Quintana JA et al.. “Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes.” JAMA cardiology (2021). PMID: 34495297 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  164. [164]

    Flynn S, Schuermans A, Uddin MM et al.. “Clonal Hematopoiesis and Incident Heart Failure.” JAMA cardiology (2026). PMID: 41206888 ↗

    L2OTHERCited in: Epidemiology and Risk Factors
  165. [165]

    Aung N, Nicholls HL, Chahal CAA et al.. “Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population.” JAMA cardiology (2024). PMID: 39196575 ↗

    L2OTHERCited in: Epidemiology and Risk Factors
  166. [166]

    Zhang C, Neuzil P, Petru J et al.. “Coronary Artery Spasm During Pulsed Field vs Radiofrequency Catheter Ablation of the Mitral Isthmus.” JAMA cardiology (2024). PMID: 38019505 ↗

    L3OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  167. [167]

    Reddy YNV, Frantz RP, Egbe AC et al.. “Phenotypic Characterization of Unclassified Pulmonary Hypertension.” Circulation. Heart failure (2026). PMID: 42318624 ↗

    L3OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism
  168. [168]

    Mentias A, Desai MY, Aminian A et al.. “Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity.” Circulation. Heart failure (2024). PMID: 38275114 ↗

    L3OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  169. [169]

    Kannan L, Shaw PA, Morley MP et al.. “Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes.” Circulation. Heart failure (2018). PMID: 30562095 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy, Prognosis and Natural History
  170. [170]

    Chamberlain AM, Redfield MM, Alonso A et al.. “Atrial fibrillation and mortality in heart failure: a community study.” Circulation. Heart failure (2011). PMID: 21920917 ↗

    L3OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History
  171. [171]

    Kyriakopoulos CP, Sideris K, Taleb I et al.. “Left Atrial Reverse Remodeling in Patients Supported With Durable Left Ventricular Assist Devices and Clinical Implications.” Circulation. Heart failure (2025). PMID: 40357557 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Complications, Prognosis and Natural History
  172. [172]

    Kodur N, Gunsalus P, Milinovich A et al.. “Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction.” Circulation. Heart failure (2025). PMID: 41178541 ↗

    L3OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Prognosis and Natural History
  173. [173]

    Ostrominski JW, Filippatos G, Claggett BL et al.. “Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction: A FINE-HEART Analysis.” JACC. Heart failure (2025). PMID: 40505158 ↗

    L1OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
  174. [174]

    Sochorová V, Kunštátová V, Osmančík P et al.. “COOPERATIVE-PFA: A Three-Arm Randomized Controlled Trial.” Circulation (2025). PMID: 40287932 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  175. [175]

    Solomon SD, Ostrominski JW, Wang X et al.. “Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.” Journal of the American College of Cardiology (2024). PMID: 39217567 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History
  176. [176]

    Cleland JGF, Bunting KV, Flather MD et al.. “Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.” European heart journal (2018). PMID: 29040525 ↗

    L1SR_OBSCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification, Prognosis and Natural History
  177. [177]

    Segan L, Kistler PM, Nanayakkara S et al.. “Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial.” European heart journal (2026). PMID: 40830055 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  178. [178]

    Pieske B, Maggioni AP, Lam CSP et al.. “Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.” European heart journal (2017). PMID: 28369340 ↗

    L1RCTCited in: Pathophysiology and Mechanism
  179. [179]

    Reddy VY, Gerstenfeld EP, Schmidt B et al.. “Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2.” Circulation (2025). PMID: 40273320 ↗

    L4TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy, Complications
  180. [180]

    Marrouche NF, Brachmann J, Andresen D et al.. “Catheter Ablation for Atrial Fibrillation with Heart Failure.” The New England journal of medicine (2018). PMID: 29385358 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Interventional and Device Therapy, Prognosis and Natural History
  181. [181]

    Zhang W, Zhang S, Deng Y et al.. “Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.” The New England journal of medicine (2021). PMID: 34491661 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation
  182. [182]

    Asfar P, Meziani F, Hamel JF et al.. “High versus low blood-pressure target in patients with septic shock.” The New England journal of medicine (2014). PMID: 24635770 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation
  183. [183]

    Andrade JG, Wells GA, Deyell MW et al.. “Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation.” The New England journal of medicine (2020). PMID: 33197159 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Special Populations and Prevention
  184. [184]

    Verma A, Jiang CY, Betts TR et al.. “Approaches to catheter ablation for persistent atrial fibrillation.” The New England journal of medicine (2015). PMID: 25946280 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Interventional and Device Therapy, Special Populations and Prevention
  185. [185]

    Pluymaekers NAHA, Dudink EAMP, Luermans JGLM et al.. “Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation.” The New England journal of medicine (2019). PMID: 30883054 ↗

    L1RCTCited in: Pathophysiology and Mechanism
  186. [186]

    Voskoboinik A, Kalman JM, De Silva A et al.. “Alcohol Abstinence in Drinkers with Atrial Fibrillation.” The New England journal of medicine (2020). PMID: 31893513 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Special Populations and Prevention
  187. [187]

    Karwath A, Bunting KV, Gill SK et al.. “Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis.” Lancet (London, England) (2021). PMID: 34474011 ↗

    L2SR_OBSCited in: Pathophysiology and Mechanism
  188. [188]

    Niiranen TJ, Schnabel RB, Schutte AE et al.. “Hypertension and Atrial Fibrillation: A Frontier Review From the AF-SCREEN International Collaboration.” Circulation (2025). PMID: 40127157 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup
  189. [189]

    Patel C, Yan GX, Kowey PR. “Dronedarone.” Circulation (2009). PMID: 19687370 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  190. [190]

    Chung MK, Eckhardt LL, Chen LY et al.. “Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association.” Circulation (2020). PMID: 32148086 ↗

    L1REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  191. [191]

    Bunch TJ. “Atrial Fibrillation and Dementia.” Circulation (2020). PMID: 32804567 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  192. [192]

    Ajoolabady A, Nattel S, Lip GYH et al.. “Inflammasome Signaling in Atrial Fibrillation: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2022). PMID: 35680186 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  193. [193]

    La Gerche A, Wasfy MM, Brosnan MJ et al.. “The Athlete's Heart-Challenges and Controversies: JACC Focus Seminar 4/4.” Journal of the American College of Cardiology (2022). PMID: 36075838 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Special Populations and Prevention
  194. [194]

    Farhan S, Silbiger JJ, Halperin JL et al.. “Pathophysiology, Echocardiographic Diagnosis, and Treatment of Atrial Functional Mitral Regurgitation: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2022). PMID: 36480974 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management
  195. [195]

    Cho L, Davis M, Elgendy I et al.. “Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2020). PMID: 32439010 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  196. [196]

    Newman JD, O'Meara E, Böhm M et al.. “Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2024). PMID: 38418008 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy
  197. [197]

    Appelboam A, Reuben A, Mann C et al.. “Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial.” Lancet (London, England) (2015). PMID: 26314489 ↗

    L1RCTCited in: Pathophysiology and Mechanism, History and Evolution of Treatment, Prognosis and Natural History
  198. [198]

    Filippatos G, Farmakis D, Butler J et al.. “Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.” European journal of heart failure (2023). PMID: 37062866 ↗

    L2RCTCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  199. [199]

    Bunting KV, Champsi A, Gill SK et al.. “Low-dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation - the RATE-AF randomized trial.” European journal of heart failure (2025). PMID: 40891341 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  200. [200]

    Bavendiek U, Thomas NH, Berliner D et al.. “DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT-HF): Baseline characteristics compared to recent randomized controlled heart failure trials.” European journal of heart failure (2025). PMID: 40389288 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  201. [201]

    Masri A, Barriales-Villa R, Elliott P et al.. “Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM.” European journal of heart failure (2024). PMID: 39023326 ↗

    L4RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  202. [202]

    Conners KM, Shearer JJ, Joo J et al.. “The Metabolic Vulnerability Index: A Novel Marker for Mortality Prediction in Heart Failure.” JACC. Heart failure (2023). PMID: 37480881 ↗

    L2SR_OBSCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Complications
  203. [203]

    Infeld M, Wahlberg K, Cicero J et al.. “Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial.” JAMA cardiology (2023). PMID: 36723919 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  204. [204]

    Matsumoto S, Henderson AD, Jhund PS et al.. “Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 40156827 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  205. [205]

    Marcus GM, Modrow MF, Schmid CH et al.. “Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation: The I-STOP-AFib Randomized Clinical Trial.” JAMA cardiology (2022). PMID: 34775507 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  206. [206]

    Kotecha D, Bunting KV, Gill SK et al.. “Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.” JAMA (2020). PMID: 33351042 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  207. [207]

    Reddy VY, Sievert H, Halperin J et al.. “Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.” JAMA (2014). PMID: 25399274 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  208. [208]

    Saberi S, Abraham TP, Choudhury L et al.. “Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.” JACC. Heart failure (2025). PMID: 40540987 ↗

    L4RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  209. [209]

    Martens P, Augusto SN, Erzeel J et al.. “Effects of Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction: Insights From CABANA.” JACC. Heart failure (2025). PMID: 40243977 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  210. [210]

    Ostrominski JW, Mc Causland FR, Claggett BL et al.. “Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial.” JACC. Heart failure (2025). PMID: 40208137 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  211. [211]

    Vaduganathan M, Claggett BL, Lam CSP et al.. “Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial.” European journal of heart failure (2024). PMID: 38742248 ↗

    L5TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy
  212. [212]

    Bertero E, Chiti C, Schiavo MA et al.. “Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.” European journal of heart failure (2024). PMID: 38131253 ↗

    L4TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  213. [213]

    Rader F, Oręziak A, Choudhury L et al.. “Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.” JACC. Heart failure (2024). PMID: 38176782 ↗

    L4TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  214. [214]

    Ho CY, Day SM, Ashley EA et al.. “Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).” Circulation (2018). PMID: 30297972 ↗

    L2OTHERCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification, Interventional and Device Therapy, History and Evolution of Treatment, Prognosis and Natural History
  215. [215]

    Reddy YNV, Carter RE, Obokata M et al.. “A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.” Circulation (2018). PMID: 29792299 ↗

    L3OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Severity Staging and Risk Stratification
  216. [216]

    Turagam MK, Neuzil P, Schmidt B et al.. “Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry.” Circulation (2023). PMID: 37199171 ↗

    L2OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
  217. [217]

    Yao C, Veleva T, Scott L et al.. “Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation.” Circulation (2018). PMID: 29802206 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  218. [218]

    Donnan GA, Fisher M, Macleod M et al.. “Stroke.” Lancet (London, England) (2008). PMID: 18468545 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy
  219. [219]

    Piccini JP, Fauchier L. “Rhythm control in atrial fibrillation.” Lancet (London, England) (2016). PMID: 27560278 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Interventional and Device Therapy
  220. [220]

    Van Gelder IC, Rienstra M, Crijns HJ et al.. “Rate control in atrial fibrillation.” Lancet (London, England) (2016). PMID: 27560277 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Interventional and Device Therapy
  221. [221]

    Nattel S, Opie LH. “Controversies in atrial fibrillation.” Lancet (London, England) (2006). PMID: 16427496 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Interventional and Device Therapy
  222. [222]

    Schmieder RE, Hilgers KF, Schlaich MP et al.. “Renin-angiotensin system and cardiovascular risk.” Lancet (London, England) (2007). PMID: 17416265 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  223. [223]

    Dobrev D, Nattel S. “New antiarrhythmic drugs for treatment of atrial fibrillation.” Lancet (London, England) (2010). PMID: 20334907 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  224. [224]

    Watson T, Shantsila E, Lip GY. “Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited.” Lancet (London, England) (2009). PMID: 19135613 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  225. [225]

    Savarese G, von Haehling S, Butler J et al.. “Iron deficiency and cardiovascular disease.” European heart journal (2023). PMID: 36282723 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification
  226. [226]

    Zeng Z, Wang X, Pei J et al.. “Endothelial plasticity in atrial fibrosis by integrating single-cell sequencing and genetic lineage tracing.” European heart journal (2025). PMID: 40626706 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  227. [227]

    Muraru D, Badano LP, Hahn RT et al.. “Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment.” European heart journal (2024). PMID: 38441886 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  228. [228]

    Vad OB, van Vreeswijk N, Yassin AS et al.. “Atrial cardiomyopathy: markers and outcomes.” European heart journal (2026). PMID: 41092306 ↗

    L2OTHERCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification
  229. [229]

    Guo J, Zhang Z, Meng X et al.. “Atrial fibrillation catheter ablation, brain glymphatic function, and cognitive performance.” European heart journal (2025). PMID: 39981927 ↗

    L3OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy
  230. [230]

    Plitt A, McGuire DK, Giugliano RP. “Atrial Fibrillation, Type 2 Diabetes, and Non-Vitamin K Antagonist Oral Anticoagulants: A Review.” JAMA cardiology (2017). PMID: 28122078 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy
  231. [231]

    Prystowsky EN, Padanilam BJ, Fogel RI. “Treatment of Atrial Fibrillation.” JAMA (2015). PMID: 26197188 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Interventional and Device Therapy
  232. [232]

    Egidy Assenza G, O'Leary E, Brida M et al.. “Survivors of Cyanotic Congenital Heart Disease: A Review.” JAMA (2026). PMID: 42258347 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  233. [233]

    Owan TE, Hodge DO, Herges RM et al.. “Trends in prevalence and outcome of heart failure with preserved ejection fraction.” The New England journal of medicine (2006). PMID: 16855265 ↗

    L4OTHERCited in: Pathophysiology and Mechanism
  234. [234]

    Marine JE. “Catheter ablation therapy for supraventricular arrhythmias.” JAMA (2007). PMID: 18165670 ↗

    L5CASE_REPORTCited in: Pathophysiology and Mechanism
  235. [235]

    Saadatagah S, Naderian M, Uddin M et al.. “Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1.” JAMA cardiology (2024). PMID: 38598228 ↗

    L2OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup
  236. [236]

    Ramonfaur D, Buckley LF, Arthur V et al.. “High Throughput Plasma Proteomics and Risk of Heart Failure and Frailty in Late Life.” JAMA cardiology (2024). PMID: 38809565 ↗

    L2OTHERCited in: Pathophysiology and Mechanism
  237. [237]

    Chen H, Li C, Han B et al.. “Circumferential Pulmonary Vein Isolation With vs Without Additional Low-Voltage-Area Ablation in Older Patients With Paroxysmal Atrial Fibrillation: A Randomized Clinical Trial.” JAMA cardiology (2023). PMID: 37378966 ↗

    L1OTHERCited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  238. [238]

    Mitchell GF, Vasan RS, Keyes MJ et al.. “Pulse pressure and risk of new-onset atrial fibrillation.” JAMA (2007). PMID: 17312290 ↗

    L2OTHERCited in: Pathophysiology and Mechanism
  239. [239]

    Sclafani M, Spartera M, Esmati Y et al.. “Weight Loss in Older Patients With Persistent Atrial Fibrillation: The LOSE-AF Randomized Clinical Trial.” JAMA (2026). PMID: 42160044 ↗

    L1OTHERCited in: Pathophysiology and Mechanism
  240. [240]

    Wang W, Zhang MJ, Inciardi RM et al.. “Association of Echocardiographic Measures of Left Atrial Function and Size With Incident Dementia.” JAMA (2022). PMID: 35315884 ↗

    L2OTHERCited in: Pathophysiology and Mechanism
  241. [241]

    Cappola AR, Fried LP, Arnold AM et al.. “Thyroid status, cardiovascular risk, and mortality in older adults.” JAMA (2006). PMID: 16507804 ↗

    L2OTHERCited in: Pathophysiology and Mechanism
  242. [242]

    Verbrugge FH, Reddy YNV, Attia ZI et al.. “Detection of Left Atrial Myopathy Using Artificial Intelligence-Enabled Electrocardiography.” Circulation. Heart failure (2021). PMID: 34911362 ↗

    L4OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Complications
  243. [243]

    Venturiello D, Vignaroli W, Nasso G. “AI-enhanced electrocardiography as a digital biomarker platform in cardiovascular medicine: clinical applications, validation gaps and future implementation pathways.” Open heart (2026). PMID: 42425720 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup
  244. [244]

    Li B, Dong Y, Chen Y et al.. “Role of NADPH oxidase 2-derived reactive oxygen species in cardiac electrophysiological disorders.” Channels (Austin, Tex.) (2026). PMID: 42405795 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  245. [245]

    Vaughan M, Kaur B, Mehta NK. “Atrial Fibrillation Risk Management and Emerging Therapies.” Journal of clinical medicine (2026). PMID: 42355780 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  246. [246]

    Cozma D, Gaita D, Crisan S et al.. “The Oxygen Imperative: Cardiorespiratory Fitness, Dose-Dependent Exercise Thresholds, and Longevity-A Narrative Review.” Journal of clinical medicine (2026). PMID: 42355766 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, History and Evolution of Treatment
  247. [247]

    Cananzi L, Greco F, Buoso A et al.. “Mediastinal adipose tissue as an active player in cardiovascular disease: a multimodality imaging narrative review.” Quantitative imaging in medicine and surgery (2026). PMID: 42433538 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  248. [248]

    Grigoriou K, Lamprou V, Antoniadis AP et al.. “Inflammasome-Driven Cardiac Fibrosis in Cardiometabolic Disease and Arrhythmias: Mechanisms, Biomarkers, and Therapeutic Targets.” Frontiers in bioscience (Landmark edition) (2026). PMID: 42411479 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  249. [249]

    Rojas SF, Khairy P. “Innovative Management of Rhythm Disorders in Adults with Congenital Heart Disease.” Methodist DeBakey cardiovascular journal (2026). PMID: 42403553 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  250. [250]

    Tokuda M, Yamashita S, Yokoyama M et al.. “Total Care Strategies in Atrial Fibrillation Practice: Lifestyle Intervention and Risk Factor Management.” Journal of cardiology (2026). PMID: 42402270 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  251. [251]

    Zheng X, Yang H, Sun H et al.. “Ethanol Infusion Into the Vein of Marshall for Atrial Fibrillation: Clinical Efficacy and Technical Limitations.” Clinical cardiology (2026). PMID: 42370746 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  252. [252]

    Ozmen C. “Circulating microRNAs in Atrial Fibrillation: Clinical Significance and Future Perspectives.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356138 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  253. [253]

    Chimura M, Jhund PS, Henderson AD et al.. “Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trial.” European journal of heart failure (2026). PMID: 41771075 ↗

    L1RCTCited in: Clinical Presentation, History and Evolution of Treatment
  254. [254]

    Metzner A, Willems S, Borof K et al.. “Diabetes and Obesity and Treatment Effect of Early Rhythm Control vs Usual Care in Patients With Atrial Fibrillation: A Secondary Analysis of the EAST-AFNET 4 Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 40737012 ↗

    L1RCTCited in: Clinical Presentation
  255. [255]

    Chatterjee NA, Chae CU, Kim E et al.. “Modifiable Risk Factors for Incident Heart Failure in Atrial Fibrillation.” JACC. Heart failure (2017). PMID: 28624486 ↗

    L2RCTCited in: Clinical Presentation
  256. [256]

    Lip GY, Tse HF, Lane DA. “Atrial fibrillation.” Lancet (London, England) (2011). PMID: 22166900 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  257. [257]

    Veselka J, Anavekar NS, Charron P. “Hypertrophic obstructive cardiomyopathy.” Lancet (London, England) (2016). PMID: 27912983 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy
  258. [258]

    Jabbour G, Nolin-Lapalme A, Tastet O et al.. “Prediction of incident atrial fibrillation using deep learning, clinical models, and polygenic scores.” European heart journal (2024). PMID: 39217446 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification
  259. [259]

    Hess PL, Healey JS, Granger CB et al.. “The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review.” JAMA cardiology (2017). PMID: 28097334 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup
  260. [260]

    Mendelson SJ, Prabhakaran S. “Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke: A Review.” JAMA (2021). PMID: 33724327 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  261. [261]

    Song J, Wang J, Wang X et al.. “Effect of the ligament of Marshall excision during minimally invasive cardiac surgery-coronary artery bypass grafting (MICS-CABG) on the prevention of postoperative new-onset atrial fibrillation (LOMEX-AF): study protocol for a randomised controlled trial.” BMJ open (2026). PMID: 42386296 ↗

    L5TRIAL_NONRANDOMCited in: Clinical Presentation, Acute and Initial Management, Interventional and Device Therapy, Prognosis and Natural History
  262. [262]

    Murphy D, Graby J, Hirst L et al.. “Assessing the impact of combined nutritional and physical activity interventions for patients with atrial fibrillation who are overweight: a systematic review protocol.” BMJ open (2026). PMID: 42336794 ↗

    L5SR_OBSCited in: Clinical Presentation
  263. [263]

    Venneri L, Aimo A, Porcari A et al.. “Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis.” European journal of heart failure (2025). PMID: 41098006 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification
  264. [264]

    Boraita A, Santos-Lozano A, Heras ME et al.. “Incidence of Atrial Fibrillation in Elite Athletes.” JAMA cardiology (2018). PMID: 30383155 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  265. [265]

    Spencer-Bonilla G, Fan J, Cheng P et al.. “Timeliness of Transthyretin Cardiac Amyloidosis Diagnosis in the Medicare Population.” JAMA cardiology (2026). PMID: 42054052 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup
  266. [266]

    Tada A, Naser JA, Doi S et al.. “Progression From Exercise-Induced to Resting Left Atrial Hypertension in HFpEF: Impact of Reduced Atriopulmonary Compliance.” JACC. Heart failure (2026). PMID: 41677477 ↗

    L2OTHERCited in: Clinical Presentation
  267. [267]

    Benfari G, Essayagh B, Tsaban G et al.. “Left Atrial Volumetric Enlargement in Heart Failure With Reduced Ejection Fraction: Obligatory Consequence or Independent Predictor of Outcome?” JACC. Heart failure (2026). PMID: 41677478 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup
  268. [268]

    Kahwash R, Butler J, Khan MS et al.. “Incidence of Cardiac Arrhythmias Identified by Insertable Cardiac Monitors in Patients With Symptomatic Heart Failure.” JACC. Heart failure (2025). PMID: 40602175 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup
  269. [269]

    Mair J. “Clinical Gray Zones of Cardiac Troponin Interpretation in the Emergency Department: When Increased Concentrations Do Not Equal Acute Coronary Syndrome.” Journal of clinical medicine (2026). PMID: 42355612 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  270. [270]

    Cayiroz K, Coteli C, Sarikaya SA et al.. “A 67-Year-Old Woman With Intractable Cough and Dyspnea After Catheter Ablation for Atrial Fibrillation.” Chest (2026). PMID: 42419860 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  271. [271]

    Curry SJ, Krist AH, Owens DK et al.. “Screening for Atrial Fibrillation With Electrocardiography: US Preventive Services Task Force Recommendation Statement.” JAMA (2018). PMID: 30088016 ↗

    L1GUIDELINECited in: Diagnosis and Workup
  272. [272]

    Sanna T, Diener HC, Passman RS et al.. “Cryptogenic stroke and underlying atrial fibrillation.” The New England journal of medicine (2014). PMID: 24963567 ↗

    L1RCTCited in: Diagnosis and Workup
  273. [273]

    Wazni OM, Chun KRJ, Nair DG et al.. “Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation.” The New England journal of medicine (2026). PMID: 42041224 ↗

    L1RCTCited in: Diagnosis and Workup
  274. [274]

    Kirchhof P, Toennis T, Goette A et al.. “Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.” The New England journal of medicine (2023). PMID: 37622677 ↗

    L1RCTCited in: Diagnosis and Workup
  275. [275]

    Meybohm P, Bein B, Brosteanu O et al.. “A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery.” The New England journal of medicine (2015). PMID: 26436208 ↗

    L1RCTCited in: Diagnosis and Workup
  276. [276]

    Zarbock A, Ostermann M, Forni L et al.. “A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial.” Lancet (London, England) (2025). PMID: 41242333 ↗

    L1RCTCited in: Diagnosis and Workup, Special Populations and Prevention
  277. [277]

    Conen D, Ke Wang M, Popova E et al.. “Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial.” Lancet (London, England) (2023). PMID: 37640035 ↗

    L1RCTCited in: Diagnosis and Workup
  278. [278]

    Verma A, Birnie DH, Jiang C et al.. “Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.” The New England journal of medicine (2025). PMID: 41211931 ↗

    L1TRIAL_NONRANDOMCited in: Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  279. [279]

    Perez MV, Mahaffey KW, Hedlin H et al.. “Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation.” The New England journal of medicine (2019). PMID: 31722151 ↗

    L2TRIAL_NONRANDOMCited in: Diagnosis and Workup
  280. [280]

    Salem JE, Shoemaker MB, Bastarache L et al.. “Association of Thyroid Function Genetic Predictors With Atrial Fibrillation: A Phenome-Wide Association Study and Inverse-Variance Weighted Average Meta-analysis.” JAMA cardiology (2019). PMID: 30673079 ↗

    L2SR_OBSCited in: Diagnosis and Workup
  281. [281]

    Cikes M, Claggett B, Shah AM et al.. “Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.” JACC. Heart failure (2018). PMID: 30007557 ↗

    L2RCTCited in: Diagnosis and Workup
  282. [282]

    Sachdev PS, Bentvelzen AC, Gustafson D et al.. “Vascular Cognitive Impairment and Dementia: Clinical Features, Neuropathology, and Biomarkers.” Journal of the American College of Cardiology (2026). PMID: 41498479 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup
  283. [283]

    Shinzato K, Takahashi Y, Yamaguchi T et al.. “Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation.” European heart journal (2025). PMID: 40392565 ↗

    L2OTHERCited in: Diagnosis and Workup
  284. [284]

    Huang B, Hao Z, Kuang Y et al.. “Intracardiac Echocardiography for Procedural Guidance of Left Atrial Appendage Occlusion From Right Atrium: A Subgroup From a Multicenter Randomized Controlled Trial With Two Intracardiac Echocardiography Imaging Systems.” Journal of cardiovascular electrophysiology (2026). PMID: 42418757 ↗

    L2RCTCited in: Diagnosis and Workup
  285. [285]

    Wang B, Cai H, Wu Y et al.. “Left atrial appendage closure with the AnchorMan or Watchman devices: 12-month results of the SAFE-PROTECT randomised trial.” EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (2026). PMID: 42405627 ↗

    L1RCTCited in: Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  286. [286]

    Attia ZI, Noseworthy PA, Lopez-Jimenez F et al.. “An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction.” Lancet (London, England) (2019). PMID: 31378392 ↗

    L3OTHERCited in: Diagnosis and Workup
  287. [287]

    Lip GY, Tse HF. “Management of atrial fibrillation.” Lancet (London, England) (2007). PMID: 17707756 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Interventional and Device Therapy, Special Populations and Prevention
  288. [288]

    Kirchhof P. “The future of atrial fibrillation management: integrated care and stratified therapy.” Lancet (London, England) (2017). PMID: 28460828 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Interventional and Device Therapy
  289. [289]

    Martens P, Olivotto I, Garcia-Pavia P et al.. “Comprehensive evaluation of hypertrophic cardiomyopathy: European Journal of Heart Failure expert consensus document.” European journal of heart failure (2026). PMID: 41818712 ↗

    L5OTHERCited in: Diagnosis and Workup, Long-term Guideline-Directed Therapy
  290. [290]

    Harada T, Reddy YNV, Sorimachi H et al.. “Dynamic tricuspid regurgitation in heart failure with preserved ejection fraction.” European journal of heart failure (2025). PMID: 40977275 ↗

    L2OTHERCited in: Diagnosis and Workup
  291. [291]

    Chang KC, Lin TT, Wang TC et al.. “Fibrosis-4 index reflects the severity of tricuspid regurgitation and patient prognosis in atrial fibrillation.” European journal of heart failure (2025). PMID: 40660086 ↗

    L2OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification, Complications
  292. [292]

    Benjamin EJ, Thomas KL, Go AS et al.. “Transforming Atrial Fibrillation Research to Integrate Social Determinants of Health: A National Heart, Lung, and Blood Institute Workshop Report.” JAMA cardiology (2023). PMID: 36478155 ↗

    L5OTHERCited in: Diagnosis and Workup
  293. [293]

    Mannina C, Ito K, Jin Z et al.. “Association of Left Atrial Strain With Ischemic Stroke Risk in Older Adults.” JAMA cardiology (2023). PMID: 36753086 ↗

    L2OTHERCited in: Diagnosis and Workup, Special Populations and Prevention
  294. [294]

    Kent DM, Wang AY. “Patent Foramen Ovale and Stroke: A Review.” JAMA (2025). PMID: 40720119 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Acute and Initial Management, History and Evolution of Treatment, Complications
  295. [295]

    Marrouche NF, Wilber D, Hindricks G et al.. “Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study.” JAMA (2014). PMID: 24496537 ↗

    L2OTHERCited in: Diagnosis and Workup, Interventional and Device Therapy
  296. [296]

    Herrmann FEM, Jeppsson A, Kirov H et al.. “Long-Term Continuous Monitoring of New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting.” JAMA (2025). PMID: 41065638 ↗

    L2OTHERCited in: Diagnosis and Workup
  297. [297]

    Rørth R, Jhund PS, Yilmaz MB et al.. “Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.” Circulation. Heart failure (2020). PMID: 32065760 ↗

    L2OTHERCited in: Diagnosis and Workup, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  298. [298]

    Qin H, Tromp J, Ter Maaten JM et al.. “Clinical and Proteomic Risk Profiles of New-Onset Heart Failure in Men and Women.” JACC. Heart failure (2024). PMID: 39708029 ↗

    L2OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification, History and Evolution of Treatment
  299. [299]

    Cikes M, Planinc I, Claggett B et al.. “Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.” JACC. Heart failure (2022). PMID: 35483796 ↗

    L2OTHERCited in: Diagnosis and Workup
  300. [300]

    King M, Martinez A, Abbruzzese S et al.. “Pulmonary Hypertension in Systemic Lupus Erythematosus Among Black and Hispanic Patients: An Observational Cohort Study.” Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2026). PMID: 42358118 ↗

    L2COHORTCited in: Diagnosis and Workup
  301. [301]

    Du H, Zeng L, Pu X. “Right atrial appendage thrombosis after percutaneous left atrial appendage occlusion: a case report.” Frontiers in cardiovascular medicine (2026). PMID: 42395878 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup
  302. [302]

    Wang P, Chen Z, Yan Y et al.. “Effect of Fluoroscopy-Only Versus Transesophageal Echocardiography/Intracardiac Echocardiography Guidance in Left Atrial Appendage Occlusion on Stroke Prevention: Analysis From the RECORD I Study.” Journal of the American Heart Association (2026). PMID: 42432454 ↗

    L2OTHERCited in: Diagnosis and Workup
  303. [303]

    Marchetta M, Filomia S, Golino M et al.. “C-reactive protein and 90-day adverse clinical outcomes in acute myocarditis: a retrospective database analysis of patients requiring hospitalisation.” Open heart (2026). PMID: 42425725 ↗

    L2OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification
  304. [304]

    Bach N, Bauermeister L, Böhnke L et al.. “Electrical and Structural Atrial Remodeling Identifies a High-Risk Phenotype in Embolic Stroke of Undetermined Source.” JACC. Advances (2026). PMID: 42425040 ↗

    L2OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification
  305. [305]

    Yu WY, Pan ML, Chen CY. “Prediction of in-hospital cardiac arrest on general wards using calibrated machine learning.” BMJ health & care informatics (2026). PMID: 42419861 ↗

    L3OTHERCited in: Diagnosis and Workup
  306. [306]

    Shimojo K, Morishima I, Morita Y et al.. “Clinical Significance of Persistent Iatrogenic Atrial Septal Defect After Catheter Ablation for Atrial Fibrillation.” Heart rhythm (2026). PMID: 42419472 ↗

    L2OTHERCited in: Diagnosis and Workup
  307. [307]

    Aulin J, Sjölin K, Lindbäck J et al.. “Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation.” Circulation (2024). PMID: 39045686 ↗

    L2RCTCited in: Severity Staging and Risk Stratification
  308. [308]

    Tang GHL, Hahn RT, Whisenant BK et al.. “Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-Year Outcomes From the TRILUMINATE Randomized Cohort.” Journal of the American College of Cardiology (2024). PMID: 39471883 ↗

    L1RCTCited in: Severity Staging and Risk Stratification, Prognosis and Natural History
  309. [309]

    Lopes RD, Granger CB, Wojdyla DM et al.. “Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA.” Journal of the American College of Cardiology (2024). PMID: 39019530 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  310. [310]

    Lip GY, Frison L, Halperin JL et al.. “Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.” Journal of the American College of Cardiology (2010). PMID: 21111555 ↗

    L2RCTCited in: Severity Staging and Risk Stratification, Special Populations and Prevention
  311. [311]

    Thyregod HG, Steinbrüchel DA, Ihlemann N et al.. “Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial.” Journal of the American College of Cardiology (2015). PMID: 25787196 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  312. [312]

    Benz AP, Hohnloser SH, Eikelboom JW et al.. “Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation.” European heart journal (2023). PMID: 37038327 ↗

    L2RCTCited in: Severity Staging and Risk Stratification, History and Evolution of Treatment, Prognosis and Natural History
  313. [313]

    Mack MJ, Leon MB, Thourani VH et al.. “Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients.” The New England journal of medicine (2019). PMID: 30883058 ↗

    L1RCTCited in: Severity Staging and Risk Stratification, Interventional and Device Therapy
  314. [314]

    Reardon MJ, Van Mieghem NM, Popma JJ et al.. “Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients.” The New England journal of medicine (2017). PMID: 28304219 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  315. [315]

    Whitlock RP, Belley-Cote EP, Paparella D et al.. “Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke.” The New England journal of medicine (2021). PMID: 33999547 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  316. [316]

    Zannad F, Anker SD, Byra WM et al.. “Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.” The New England journal of medicine (2018). PMID: 30146935 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  317. [317]

    Friberg L, Rosenqvist M, Lip GY. “Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.” European heart journal (2012). PMID: 22246443 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification
  318. [318]

    Hijazi Z, Oldgren J, Lindbäck J et al.. “The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.” Lancet (London, England) (2016). PMID: 27056738 ↗

    L2RCTCited in: Severity Staging and Risk Stratification
  319. [319]

    Lopes RD, Al-Khatib SM, Wallentin L et al.. “Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.” Lancet (London, England) (2012). PMID: 23036896 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  320. [320]

    Mant J, Hobbs FD, Fletcher K et al.. “Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.” Lancet (London, England) (2007). PMID: 17693178 ↗

    L1RCTCited in: Severity Staging and Risk Stratification, Special Populations and Prevention
  321. [321]

    Connolly S, Pogue J, Hart R et al.. “Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.” Lancet (London, England) (2006). PMID: 16765759 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  322. [322]

    Mega JL, Walker JR, Ruff CT et al.. “Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.” Lancet (London, England) (2015). PMID: 25769357 ↗

    L2RCTCited in: Severity Staging and Risk Stratification
  323. [323]

    Myhre PL, Vaduganathan M, Claggett BL et al.. “Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.” JAMA cardiology (2018). PMID: 30140899 ↗

    L2RCTCited in: Severity Staging and Risk Stratification
  324. [324]

    Abed HS, Wittert GA, Leong DP et al.. “Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial.” JAMA (2013). PMID: 24240932 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  325. [325]

    Freund Y, Cachanado M, Delannoy Q et al.. “Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure: The ELISABETH Randomized Clinical Trial.” JAMA (2020). PMID: 33201202 ↗

    L1RCTCited in: Severity Staging and Risk Stratification, Special Populations and Prevention
  326. [326]

    Čelutkienė J, Čerlinskaitė-Bajorė K, Cotter G et al.. “Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial.” Circulation. Heart failure (2024). PMID: 38445950 ↗

    L1RCTCited in: Severity Staging and Risk Stratification
  327. [327]

    Santos AB, Roca GQ, Claggett B et al.. “Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.” Circulation. Heart failure (2016). PMID: 27056882 ↗

    L2RCTCited in: Severity Staging and Risk Stratification, History and Evolution of Treatment
  328. [328]

    Lee DS, Hardy J, Yee R et al.. “Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators.” Circulation. Heart failure (2015). PMID: 26224792 ↗

    L2RCTCited in: Severity Staging and Risk Stratification, Interventional and Device Therapy, Prognosis and Natural History, Special Populations and Prevention
  329. [329]

    Mamas MA, Caldwell JC, Chacko S et al.. “A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure.” European journal of heart failure (2009). PMID: 19553398 ↗

    L2SR_OBSCited in: Severity Staging and Risk Stratification
  330. [330]

    Schnabel RB, Sullivan LM, Levy D et al.. “Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study.” Lancet (London, England) (2009). PMID: 19249635 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification
  331. [331]

    Ludwig S, Klimek M, Bay B et al.. “Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk: An Individual Participant Data Meta-Analysis.” JAMA cardiology (2025). PMID: 40884787 ↗

    L1SR_OBSCited in: Severity Staging and Risk Stratification, Interventional and Device Therapy
  332. [332]

    Hsu JC, Maddox TM, Kennedy KF et al.. “Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry.” JAMA cardiology (2016). PMID: 27437655 ↗

    L2SR_OBSCited in: Severity Staging and Risk Stratification
  333. [333]

    Kristensen SL, Mogensen UM, Jhund PS et al.. “N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.” Circulation. Heart failure (2019). PMID: 30871349 ↗

    L2SR_OBSCited in: Severity Staging and Risk Stratification, Prognosis and Natural History
  334. [334]

    Park H, Norby FL, Kim D et al.. “Proteomic Signatures for Risk Prediction of Atrial Fibrillation.” Circulation (2025). PMID: 40401370 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  335. [335]

    Khurshid S, Friedman S, Reeder C et al.. “ECG-Based Deep Learning and Clinical Risk Factors to Predict Atrial Fibrillation.” Circulation (2021). PMID: 34743566 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  336. [336]

    Dardari ZA, Yao Z, Zhang J et al.. “Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration.” Circulation (2026). PMID: 41674444 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  337. [337]

    Aggarwal R, Ruff CT, Virdone S et al.. “Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants.” Circulation (2023). PMID: 37621213 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  338. [338]

    Siontis KC, Zhang X, Eckard A et al.. “Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.” Circulation (2018). PMID: 29954737 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  339. [339]

    Beeche C, Zhao B, Tavolinejad H et al.. “Early Vascular Aging Determined by 3-Dimensional Aortic Geometry: Genetic Determinants and Clinical Consequences.” Circulation (2025). PMID: 40671674 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  340. [340]

    Mohammadi-Shemirani P, Chong M, Narula S et al.. “Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study.” Journal of the American College of Cardiology (2022). PMID: 35450575 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  341. [341]

    Chang SH, Kuo CF, Chou IJ et al.. “Association of a Family History of Atrial Fibrillation With Incidence and Outcomes of Atrial Fibrillation: A Population-Based Family Cohort Study.” JAMA cardiology (2017). PMID: 28678986 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification
  342. [342]

    Segan L, Canovas R, Nanayakkara S et al.. “New-onset atrial fibrillation prediction: the HARMS2-AF risk score.” European heart journal (2023). PMID: 37350480 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  343. [343]

    Wang N, Sun Y, Zhang H et al.. “Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease.” European heart journal (2021). PMID: 34374755 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  344. [344]

    Wang Y, Ding C, Liu Y et al.. “Bidirectional association between COPD and AF: a systematic review and meta-analysis.” Frontiers in cardiovascular medicine (2026). PMID: 42403902 ↗

    L2SR_OBSCited in: Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  345. [345]

    Freedman B, Potpara TS, Lip GY. “Stroke prevention in atrial fibrillation.” Lancet (London, England) (2016). PMID: 27560276 ↗

    L5REVIEW_NARRATIVECited in: Severity Staging and Risk Stratification
  346. [346]

    Tawfiq E, Selak V, Elwood JM et al.. “Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study.” Lancet (London, England) (2023). PMID: 36702148 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  347. [347]

    Tuna MA, Rothwell PM. “Diagnosis of non-consensus transient ischaemic attacks with focal, negative, and non-progressive symptoms: population-based validation by investigation and prognosis.” Lancet (London, England) (2021). PMID: 33676629 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  348. [348]

    Lu R, Lumish HS, Hasegawa K et al.. “Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using machine learning.” European journal of heart failure (2024). PMID: 39694602 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  349. [349]

    Cai A, Qiu W, Zhou Y et al.. “Clinical characteristics and 1-year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association Database-Heart Failure Center Registry.” European journal of heart failure (2022). PMID: 36054149 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  350. [350]

    Gao Q, Wang Y, Zhao Y et al.. “Risk of Stroke, Thromboembolism and Mortality in Atrial Fibrillation Patients Across Different Stages and Types of Heart Failure: A Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 42278998 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification
  351. [351]

    Katarzyna G, Ewa D, Mateusz W et al.. “Risk-score performance for detecting transthyretin cardiac amyloidosis in severe aortic stenosis: a prospective cohort study.” Frontiers in cardiovascular medicine (2026). PMID: 42257036 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification
  352. [352]

    Vad OB, Monfort LM, Paludan-Müller C et al.. “Rare and Common Genetic Variation Underlying Atrial Fibrillation Risk.” JAMA cardiology (2024). PMID: 38922602 ↗

    L3OTHERCited in: Severity Staging and Risk Stratification
  353. [353]

    Zhang R, Kim MS, Yin W et al.. “Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation.” JAMA cardiology (2025). PMID: 41060636 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  354. [354]

    Butt JH, Olesen JB, Gundlund A et al.. “Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Left-Sided Heart Valve Surgery.” JAMA cardiology (2019). PMID: 31596426 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  355. [355]

    Abdel-Qadir H, Singh SM, Pang A et al.. “Evaluation of the Risk of Stroke Without Anticoagulation Therapy in Men and Women With Atrial Fibrillation Aged 66 to 74 Years Without Other CHA2DS2-VASc Factors.” JAMA cardiology (2021). PMID: 34009232 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  356. [356]

    Ellervik C, Roselli C, Christophersen IE et al.. “Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation: A Mendelian Randomization Study.” JAMA cardiology (2019). PMID: 30673084 ↗

    L3OTHERCited in: Severity Staging and Risk Stratification
  357. [357]

    Själander S, Holmqvist F, Smith JG et al.. “Assessment of Use vs Discontinuation of Oral Anticoagulation After Pulmonary Vein Isolation in Patients With Atrial Fibrillation.” JAMA cardiology (2017). PMID: 27893055 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  358. [358]

    Honigberg MC, Zekavat SM, Aragam K et al.. “Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.” JAMA (2019). PMID: 31738818 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  359. [359]

    Walkey AJ, Wiener RS, Ghobrial JM et al.. “Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis.” JAMA (2011). PMID: 22081378 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  360. [360]

    Xian Y, O'Brien EC, Liang L et al.. “Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation.” JAMA (2017). PMID: 28291892 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  361. [361]

    Melgaard L, Gorst-Rasmussen A, Lane DA et al.. “Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.” JAMA (2015). PMID: 26318604 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  362. [362]

    Fauvel C, Jaque PC, Liu Y et al.. “Refining the Definition for "Low Risk" in Pulmonary Arterial Hypertension: Time to Reduce Morbidity and Mortality.” JACC. Heart failure (2026). PMID: 42171541 ↗

    L1OTHERCited in: Severity Staging and Risk Stratification
  363. [363]

    Zile MR, Kahwash R, Sarkar S et al.. “A Novel Heart Failure Diagnostic Risk Score Using a Minimally Invasive Subcutaneous Insertable Cardiac Monitor.” JACC. Heart failure (2023). PMID: 37943225 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  364. [364]

    Zile MR, Kahwash R, Sarkar S et al.. “Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure.” JACC. Heart failure (2023). PMID: 36752485 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  365. [365]

    Tada A, Doi S, Harada T et al.. “Autoimmune Disorders in Heart Failure With Preserved Ejection Fraction.” JACC. Heart failure (2024). PMID: 38819353 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  366. [366]

    Pandey A, Kim S, Moore C et al.. “Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation.” JACC. Heart failure (2017). PMID: 28034376 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification
  367. [367]

    Dastjerdi P, Tavakoli K, Narimani-Javid R et al.. “Functional mitral valve regurgitation outcomes by treatment modality: a systematic review and meta-analysis of reconstructed survival data.” BMC cardiovascular disorders (2026). PMID: 42321618 ↗

    L2SR_OBSCited in: Severity Staging and Risk Stratification, History and Evolution of Treatment
  368. [368]

    Du Y, Yang F, Liu Y. “Correlation of composite inflammatory indices and homocysteine with the severity of acute ischemic stroke: A retrospective study.” Medicine (2026). PMID: 42260856 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification
  369. [369]

    Rashedi S, Keykhaei M, Sato A et al.. “Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials.” Journal of the American College of Cardiology (2025). PMID: 39918465 ↗

    L1SR_OBSCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
  370. [370]

    Benali K, Khairy P, Hammache N et al.. “Procedure-Related Complications of Catheter Ablation for Atrial Fibrillation.” Journal of the American College of Cardiology (2023). PMID: 37225362 ↗

    L1SR_OBSCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications
  371. [371]

    Dehbi HM, Fischer U, Åsberg S et al.. “Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST).” Lancet (London, England) (2025). PMID: 40570866 ↗

    L1SR_MA_RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History, Special Populations and Prevention
  372. [372]

    Reddy VY, Calkins H, Mansour M et al.. “Pulsed Field Ablation to Treat Paroxysmal Atrial Fibrillation: Safety and Effectiveness in the AdmIRE Pivotal Trial.” Circulation (2024). PMID: 39258362 ↗

    L2TRIAL_NONRANDOMCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications
  373. [373]

    Granger CB, Alexander JH, McMurray JJ et al.. “Apixaban versus warfarin in patients with atrial fibrillation.” The New England journal of medicine (2011). PMID: 21870978 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  374. [374]

    Connolly SJ, Sharma M, Cohen AT et al.. “Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.” The New England journal of medicine (2024). PMID: 38749032 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  375. [375]

    Ruff CT, Giugliano RP, Braunwald E et al.. “Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.” Lancet (London, England) (2013). PMID: 24315724 ↗

    L1SR_OBSCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  376. [376]

    Nogueira RG, Jovin TG, Liu X et al.. “Endovascular therapy for acute vertebrobasilar occlusion (VERITAS): a systematic review and individual patient data meta-analysis.” Lancet (London, England) (2024). PMID: 39674187 ↗

    L1SR_OBSCited in: Acute and Initial Management, Prognosis and Natural History
  377. [377]

    Veltkamp R, Korompoki E, Harvey KH et al.. “Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.” Lancet (London, England) (2025). PMID: 40023176 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  378. [378]

    Piccini JP, Patel MR, Steffel J et al.. “Asundexian versus Apixaban in Patients with Atrial Fibrillation.” The New England journal of medicine (2024). PMID: 39225267 ↗

    L1TRIAL_NONRANDOMCited in: Acute and Initial Management
  379. [379]

    Kistler PM, Chieng D, Sugumar H et al.. “Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The CAPLA Randomized Clinical Trial.” JAMA (2023). PMID: 36625809 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment
  380. [380]

    Mato AR, Shah NN, Jurczak W et al.. “Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.” Lancet (London, England) (2021). PMID: 33676628 ↗

    L4TRIAL_NONRANDOMCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  381. [381]

    Wang M, Rule S, Zinzani PL et al.. “Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.” Lancet (London, England) (2017). PMID: 29241979 ↗

    L4TRIAL_NONRANDOMCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
  382. [382]

    Bavendiek U, Berliner D, Dávila LA et al.. “Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study.” European journal of heart failure (2019). PMID: 30892806 ↗

    L5TRIAL_NONRANDOMCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  383. [383]

    Deftereos SG, Beerkens FJ, Shah B et al.. “Colchicine in Cardiovascular Disease: In-Depth Review.” Circulation (2021). PMID: 34965168 ↗

    L5REVIEW_NARRATIVECited in: Acute and Initial Management, Long-term Guideline-Directed Therapy
  384. [384]

    Verma A, Haines DE, Boersma LV et al.. “Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial.” Circulation (2023). PMID: 36877118 ↗

    L4OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  385. [385]

    Reddy VY, Neuzil P, Koruth JS et al.. “Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation.” Journal of the American College of Cardiology (2019). PMID: 31085321 ↗

    L4OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  386. [386]

    Imazio M, Nidorf M. “Colchicine and the heart.” European heart journal (2021). PMID: 33961006 ↗

    L5REVIEW_NARRATIVECited in: Acute and Initial Management
  387. [387]

    Landmesser U, Skurk C, Tzikas A et al.. “Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives.” European heart journal (2024). PMID: 39027946 ↗

    L5REVIEW_NARRATIVECited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  388. [388]

    Becher N, Metzner A, Toennis T et al.. “Atrial fibrillation burden: a new outcome predictor and therapeutic target.” European heart journal (2024). PMID: 38953776 ↗

    L5REVIEW_NARRATIVECited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Prognosis and Natural History
  389. [389]

    Alomairi AA, Alduhaysh R, Samandar A et al.. “Cerebrovascular and Bleeding Outcomes of Warfarin versus Direct Oral Anticoagulants Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Neurosciences (Riyadh, Saudi Arabia) (2026). PMID: 42415975 ↗

    L1SR_MA_RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  390. [390]

    Cueva-Cañola LE, Tapia C, Torres Castro AP et al.. “Colchicine in cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials.” Medicina clinica (2026). PMID: 42413351 ↗

    L1SR_MA_RCTCited in: Acute and Initial Management, Complications
  391. [391]

    Kochkarian T, Ismail A, Chaabo O et al.. “Personalized Antithrombotic Therapy After Percutaneous Coronary Intervention: A Systematic Review of Risk-Stratified Approaches.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 42410742 ↗

    L5SR_OBSCited in: Acute and Initial Management, History and Evolution of Treatment
  392. [392]

    Wang L, Cheng Y, Wan S et al.. “Joint trajectories of sleep quality and cognitive function after acute ischemic stroke: a prospective cohort study using group-based dual trajectory modeling.” Frontiers in medicine (2026). PMID: 42433978 ↗

    L2COHORTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  393. [393]

    Song H, Gao S, Yang Z et al.. “Association between Cabrol shunt and new-onset atrial fibrillation after acute type A aortic dissection surgery: a retrospective study.” Frontiers in cardiovascular medicine (2026). PMID: 42375852 ↗

    L3COHORTCited in: Acute and Initial Management
  394. [394]

    Bikdeli B, Zahedi Tajrishi F, Sadeghipour P et al.. “Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.” JAMA cardiology (2022). PMID: 35648414 ↗

    L5REVIEW_NARRATIVECited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  395. [395]

    Burashnikov A, Di Diego JM, Barajas-Martínez H et al.. “Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.” Circulation. Heart failure (2014). PMID: 24874201 ↗

    L5OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  396. [396]

    Shah P, Zheng Y, Pieske B et al.. “Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy.” Circulation. Heart failure (2025). PMID: 41058565 ↗

    L4OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy
  397. [397]

    Ezekowitz JA, Hu J, Delgado D et al.. “Acute heart failure: perspectives from a randomized trial and a simultaneous registry.” Circulation. Heart failure (2012). PMID: 23032196 ↗

    L2OTHERCited in: Acute and Initial Management
  398. [398]

    Avula V, Sharma G, Kosiborod MN et al.. “SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction.” JACC. Heart failure (2023). PMID: 37897456 ↗

    L3OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  399. [399]

    Birnie DH, Healey JS, Wells GA et al.. “Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2).” European heart journal (2018). PMID: 30462279 ↗

    L1RCTCited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Prognosis and Natural History
  400. [400]

    Gaudino M, Sanna T, Ballman KV et al.. “Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial.” Lancet (London, England) (2021). PMID: 34788640 ↗

    L1RCTCited in: Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  401. [401]

    Tucker WJ, Fegers-Wustrow I, Halle M et al.. “Exercise for Primary and Secondary Prevention of Cardiovascular Disease: JACC Focus Seminar 1/4.” Journal of the American College of Cardiology (2022). PMID: 36075680 ↗

    L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy, Special Populations and Prevention
  402. [402]

    Bejjani A, Khairani CD, Assi A et al.. “When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2024). PMID: 38233019 ↗

    L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy, Complications
  403. [403]

    Doherty JU, Gluckman TJ, Hucker WJ et al.. “2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force.” Journal of the American College of Cardiology (2017). PMID: 28081965 ↗

    L1OTHERCited in: Long-term Guideline-Directed Therapy
  404. [404]

    Wazni OM, Saliba WI, Nair DG et al.. “Left Atrial Appendage Closure after Ablation for Atrial Fibrillation.” The New England journal of medicine (2024). PMID: 39555822 ↗

    L1OTHERCited in: Long-term Guideline-Directed Therapy
  405. [405]

    Reddy VY, Gerstenfeld EP, Natale A et al.. “Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation.” The New England journal of medicine (2023). PMID: 37634148 ↗

    L1OTHERCited in: Long-term Guideline-Directed Therapy
  406. [406]

    Lian LY, Chen QF, Xia T et al.. “Trajectory of liver-related events following incident cardiovascular disease in MASLD: A 15-year population-based cohort study.” Metabolism: clinical and experimental (2026). PMID: 42431256 ↗

    L2COHORTCited in: Long-term Guideline-Directed Therapy
  407. [407]

    Song Y, Zheng Z, Cui K et al.. “Associations between prediabetes, type 2 diabetes, and incident arrhythmias: a population-based cohort study and Mendelian randomization analysis.” Diabetes research and clinical practice (2026). PMID: 42431242 ↗

    L2COHORTCited in: Long-term Guideline-Directed Therapy
  408. [408]

    Cinza-Sanjurjo S, Mazón-Ramos P, Rey-Aldana D et al.. “Impact of Primary Care Physician Continuity on Survival in Patients with Atrial Fibrillation: A Retrospective Cohort Study.” European heart journal. Quality of care & clinical outcomes (2026). PMID: 42426552 ↗

    L3COHORTCited in: Long-term Guideline-Directed Therapy, Prognosis and Natural History
  409. [409]

    Huffman MD, Malaisrie SC, Karmali KN. “Concomitant Atrial Fibrillation Surgery for People Undergoing Cardiac Surgery.” JAMA cardiology (2017). PMID: 28196179 ↗

    L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy
  410. [410]

    Kent DM, Saver JL, Kasner SE et al.. “Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke.” JAMA (2021). PMID: 34905030 ↗

    L1OTHERCited in: Long-term Guideline-Directed Therapy, Special Populations and Prevention
  411. [411]

    Kamel H, Longstreth WT, Tirschwell DL et al.. “Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial.” JAMA (2024). PMID: 38324415 ↗

    L1OTHERCited in: Long-term Guideline-Directed Therapy
  412. [412]

    Karthikeyan G, Ntsekhe M, Islam S et al.. “Mortality and Morbidity in Adults With Rheumatic Heart Disease.” JAMA (2024). PMID: 38837131 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy
  413. [413]

    Zheng J, Heidenreich PA, Kohsaka S et al.. “Long-Term Outcomes of Early Coronary Artery Disease Testing After New-Onset Heart Failure.” Circulation. Heart failure (2023). PMID: 37212148 ↗

    L3OTHERCited in: Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  414. [414]

    Keefe JA, Garber R, McCauley MD et al.. “Tachycardia and Atrial Fibrillation-Related Cardiomyopathies: Potential Mechanisms and Current Therapies.” JACC. Heart failure (2024). PMID: 38206235 ↗

    L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications
  415. [415]

    Halahakone U, Borg SJ, Senanayake S et al.. “Health Care Workers' Preferences in the Delivery of Atrial Fibrillation Screening: A Systematic Review.” Heart, lung & circulation (2026). PMID: 42392917 ↗

    L4SR_OBSCited in: Long-term Guideline-Directed Therapy
  416. [416]

    Lopiano C, Pezzuto B, Muratori M et al.. “The Hidden Burden of Iatrogenic Atrial Shunting in Severe Tricuspid Regurgitation: A Case Report.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 42419354 ↗

    L4CASE_REPORTCited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy
  417. [417]

    Zhou Y, Houle J, Raparelli V et al.. “Clustering of Social Determinants of Health and Their Association With Adverse Cardiovascular Outcomes in Atrial Fibrillation.” Journal of the American Heart Association (2026). PMID: 42432436 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy
  418. [418]

    Steffel J, Verhamme P, Potpara TS et al.. “The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.” European heart journal (2018). PMID: 29562325 ↗

    L1GUIDELINECited in: Interventional and Device Therapy, History and Evolution of Treatment, Complications
  419. [419]

    Prabhu S, Taylor AJ, Costello BT et al.. “Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study.” Journal of the American College of Cardiology (2017). PMID: 28855115 ↗

    L1RCTCited in: Interventional and Device Therapy
  420. [420]

    Reddy VY, Mansour M, Calkins H et al.. “Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden.” Journal of the American College of Cardiology (2024). PMID: 38864538 ↗

    L1RCTCited in: Interventional and Device Therapy
  421. [421]

    Cappato R, Marchlinski FE, Hohnloser SH et al.. “Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.” European heart journal (2015). PMID: 25975659 ↗

    L1RCTCited in: Interventional and Device Therapy, History and Evolution of Treatment
  422. [422]

    Brignole M, Pentimalli F, Palmisano P et al.. “AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial.” European heart journal (2021). PMID: 34453840 ↗

    L1RCTCited in: Interventional and Device Therapy, History and Evolution of Treatment, Prognosis and Natural History
  423. [423]

    Reddy VY, Anic A, Koruth J et al.. “Pulsed Field Ablation in Patients With Persistent Atrial Fibrillation.” Journal of the American College of Cardiology (2020). PMID: 32854842 ↗

    L4TRIAL_NONRANDOMCited in: Interventional and Device Therapy
  424. [424]

    Fudim M, Dalgaard F, Friedman DJ et al.. “Comorbidities and clinical response to cardiac resynchronization therapy: Patient-level meta-analysis from eight clinical trials.” European journal of heart failure (2023). PMID: 37671601 ↗

    L1TRIAL_NONRANDOMCited in: Interventional and Device Therapy
  425. [425]

    Calkins H, Willems S, Gerstenfeld EP et al.. “Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.” The New England journal of medicine (2017). PMID: 28317415 ↗

    L1RCTCited in: Interventional and Device Therapy
  426. [426]

    Kuck KH, Brugada J, Fürnkranz A et al.. “Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation.” The New England journal of medicine (2016). PMID: 27042964 ↗

    L1RCTCited in: Interventional and Device Therapy
  427. [427]

    Healey JS, Connolly SJ, Gold MR et al.. “Subclinical atrial fibrillation and the risk of stroke.” The New England journal of medicine (2012). PMID: 22236222 ↗

    L2RCTCited in: Interventional and Device Therapy
  428. [428]

    Yasuda S, Kaikita K, Akao M et al.. “Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.” The New England journal of medicine (2019). PMID: 31475793 ↗

    L1RCTCited in: Interventional and Device Therapy
  429. [429]

    Chatterjee NA, Upadhyay GA, Ellenbogen KA et al.. “Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode.” European journal of heart failure (2012). PMID: 22436544 ↗

    L1SR_OBSCited in: Interventional and Device Therapy
  430. [430]

    Vranckx P, Valgimigli M, Eckardt L et al.. “Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.” Lancet (London, England) (2019). PMID: 31492505 ↗

    L1RCTCited in: Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  431. [431]

    Gouda P, Alemayehu W, Voors AA et al.. “Implantable cardioverter-defibrillators in ischaemic versus non-ischaemic heart failure: Insights from the VICTORIA trial.” European journal of heart failure (2025). PMID: 40539883 ↗

    L2RCTCited in: Interventional and Device Therapy
  432. [432]

    Sciacca V, Sohns C, Crijns HJGM et al.. “Effects of atrial fibrillation ablation on arrhythmia burden and ventricular function in end-stage heart failure: Lessons from CASTLE-HTx.” European journal of heart failure (2024). PMID: 39444312 ↗

    L1RCTCited in: Interventional and Device Therapy
  433. [433]

    Amit G, Nyong J, Morillo CA. “Efficacy of Catheter Ablation for Nonparoxysmal Atrial Fibrillation.” JAMA cardiology (2017). PMID: 28423144 ↗

    L5SR_OBSCited in: Interventional and Device Therapy
  434. [434]

    Turagam MK, Musikantow D, Whang W et al.. “Assessment of Catheter Ablation or Antiarrhythmic Drugs for First-line Therapy of Atrial Fibrillation: A Meta-analysis of Randomized Clinical Trials.” JAMA cardiology (2021). PMID: 33909022 ↗

    L1SR_OBSCited in: Interventional and Device Therapy
  435. [435]

    Lopes RD, Hong H, Harskamp RE et al.. “Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.” JAMA cardiology (2020). PMID: 32101251 ↗

    L1SR_OBSCited in: Interventional and Device Therapy
  436. [436]

    Valderrábano M, Peterson LE, Swarup V et al.. “Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial.” JAMA (2020). PMID: 33107945 ↗

    L1RCTCited in: Interventional and Device Therapy
  437. [437]

    Al-Kaisey AM, Parameswaran R, Bryant C et al.. “Atrial Fibrillation Catheter Ablation vs Medical Therapy and Psychological Distress: A Randomized Clinical Trial.” JAMA (2023). PMID: 37698564 ↗

    L1RCTCited in: Interventional and Device Therapy
  438. [438]

    Lakkireddy DR, Wilber DJ, Mittal S et al.. “Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation: The aMAZE Randomized Clinical Trial.” JAMA (2024). PMID: 38563835 ↗

    L1RCTCited in: Interventional and Device Therapy
  439. [439]

    Healey JS, Hohnloser SH, Exner DV et al.. “Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT).” Circulation. Heart failure (2012). PMID: 22896584 ↗

    L1RCTCited in: Interventional and Device Therapy
  440. [440]

    Birnie DH, Ha A, Higginson L et al.. “Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).” Circulation. Heart failure (2013). PMID: 23995437 ↗

    L2RCTCited in: Interventional and Device Therapy
  441. [441]

    Conraads VM, Spruit MA, Braunschweig F et al.. “Physical activity measured with implanted devices predicts patient outcome in chronic heart failure.” Circulation. Heart failure (2014). PMID: 24519908 ↗

    L2RCTCited in: Interventional and Device Therapy
  442. [442]

    Chieng D, Sugumar H, Segan L et al.. “Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial.” JACC. Heart failure (2023). PMID: 36868916 ↗

    L1RCTCited in: Interventional and Device Therapy
  443. [443]

    Ivanovski M, Mrak M, Mežnar AZ et al.. “The CONDUCT-AF trial: Rationale and design of a prospective, randomized, multicentre study comparing conduction system and biventricular pacing in patients undergoing atrioventricular node ablation for heart failure with atrial fibrillation.” European journal of heart failure (2025). PMID: 40920457 ↗

    L5TRIAL_NONRANDOMCited in: Interventional and Device Therapy
  444. [444]

    Asad ZUA, Bhamare A, Qamar U et al.. “Pulmonary Vein Isolation Plus Adjunct Techniques Versus Pulmonary Vein Isolation Alone for Persistent Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of cardiovascular electrophysiology (2026). PMID: 42418771 ↗

    L1SR_MA_RCTCited in: Interventional and Device Therapy
  445. [445]

    Reddy VY, Petru J, Funasako M et al.. “Coronary Arterial Spasm During Pulsed Field Ablation to Treat Atrial Fibrillation.” Circulation (2022). PMID: 36134574 ↗

    L4OTHERCited in: Interventional and Device Therapy
  446. [446]

    Reddy VY, Gerstenfeld EP, Schmidt B et al.. “Pulsed Field Ablation for Persistent Atrial Fibrillation: 1-Year Results of ADVANTAGE AF.” Journal of the American College of Cardiology (2025). PMID: 40306839 ↗

    L4OTHERCited in: Interventional and Device Therapy, History and Evolution of Treatment
  447. [447]

    Di Biase L, Lakkireddy DJ, Marazzato J et al.. “Antithrombotic Therapy for Patients Undergoing Cardiac Electrophysiological and Interventional Procedures: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2024). PMID: 38171713 ↗

    L5REVIEW_NARRATIVECited in: Interventional and Device Therapy
  448. [448]

    Kanaoka K, Nishida T, Iwanaga Y et al.. “Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks.” European heart journal (2024). PMID: 38117227 ↗

    L3OTHERCited in: Interventional and Device Therapy
  449. [449]

    Obokata M, Reddy YNV, Yang JH et al.. “Left Atrial Contracture or Failure to Dilate.” Circulation. Heart failure (2018). PMID: 30354368 ↗

    L4CASE_REPORTCited in: Interventional and Device Therapy
  450. [450]

    Lee G, Sanders P, Kalman JM. “Catheter ablation of atrial arrhythmias: state of the art.” Lancet (London, England) (2012). PMID: 23101718 ↗

    L5REVIEW_NARRATIVECited in: Interventional and Device Therapy
  451. [451]

    Verheugt FW, Granger CB. “Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.” Lancet (London, England) (2015). PMID: 25777666 ↗

    L5REVIEW_NARRATIVECited in: Interventional and Device Therapy, Special Populations and Prevention
  452. [452]

    von Stein P, Weimann J, Pfister R et al.. “Prognostic value of NT-proBNP in patients with primary mitral regurgitation undergoing transcatheter edge-to-edge repair.” European journal of heart failure (2025). PMID: 40533899 ↗

    L2OTHERCited in: Interventional and Device Therapy
  453. [453]

    Packer M. “Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment.” European journal of heart failure (2019). PMID: 31849132 ↗

    L5REVIEW_NARRATIVECited in: Interventional and Device Therapy
  454. [454]

    Liu LC, Damman K, Lipsic E et al.. “Heart failure highlights in 2012-2013.” European journal of heart failure (2013). PMID: 24464645 ↗

    L5REVIEW_NARRATIVECited in: Interventional and Device Therapy
  455. [455]

    Filippatos G, Birnie D, Gold MR et al.. “Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing.” European journal of heart failure (2017). PMID: 28708290 ↗

    L5REVIEW_NARRATIVECited in: Interventional and Device Therapy
  456. [456]

    Assaf A, Feng H, Bsoul M et al.. “Characterization of arrhythmia-induced cardiomyopathy using magnetic resonance imaging in patients with persistent atrial fibrillation and left ventricular systolic dysfunction - insights from DECAAF II.” European journal of heart failure (2025). PMID: 40356053 ↗

    L2OTHERCited in: Interventional and Device Therapy
  457. [457]

    von Olshausen G, Benson L, Dahlström U et al.. “Catheter ablation for patients with atrial fibrillation and heart failure: insights from the Swedish Heart Failure Registry.” European journal of heart failure (2022). PMID: 35779270 ↗

    L2OTHERCited in: Interventional and Device Therapy
  458. [458]

    Turagam MK, Neuzil P, Schmidt B et al.. “Clinical Outcomes by Sex After Pulsed Field Ablation of Atrial Fibrillation.” JAMA cardiology (2023). PMID: 37910101 ↗

    L2OTHERCited in: Interventional and Device Therapy
  459. [459]

    Arnold SV, Li Z, Vemulapalli S et al.. “Association of Transcatheter Mitral Valve Repair With Quality of Life Outcomes at 30 Days and 1 Year: Analysis of the Transcatheter Valve Therapy Registry.” JAMA cardiology (2018). PMID: 30476950 ↗

    L2OTHERCited in: Interventional and Device Therapy
  460. [460]

    Butters A, Semsarian CR, Bagnall RD et al.. “Clinical Profile and Health Disparities in a Multiethnic Cohort of Patients With Hypertrophic Cardiomyopathy.” Circulation. Heart failure (2021). PMID: 33724884 ↗

    L2OTHERCited in: Interventional and Device Therapy
  461. [461]

    Khazanie P, Greiner MA, Al-Khatib SM et al.. “Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.” Circulation. Heart failure (2016). PMID: 27296396 ↗

    L2OTHERCited in: Interventional and Device Therapy, Special Populations and Prevention
  462. [462]

    Georgiopoulou VV, Kalogeropoulos AP, Giamouzis G et al.. “Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy.” Circulation. Heart failure (2009). PMID: 19808323 ↗

    L2OTHERCited in: Interventional and Device Therapy
  463. [463]

    Klein L, Grau-Sepulveda MV, Bonow RO et al.. “Quality of care and outcomes in women hospitalized for heart failure.” Circulation. Heart failure (2011). PMID: 21862732 ↗

    L2OTHERCited in: Interventional and Device Therapy
  464. [464]

    Ariyaratnam JP, Mishima RS, Kadhim K et al.. “Utility and Validity of the HFA-PEFF and H2FPEF Scores in Patients With Symptomatic Atrial Fibrillation.” JACC. Heart failure (2024). PMID: 38520461 ↗

    L3OTHERCited in: Interventional and Device Therapy
  465. [465]

    Normand C, Linde C, Singh J et al.. “Indications for Cardiac Resynchronization Therapy: A Comparison of the Major International Guidelines.” JACC. Heart failure (2018). PMID: 29598935 ↗

    L5OTHERCited in: Interventional and Device Therapy
  466. [466]

    Ariyaratnam JP, Elliott AD, Mishima RS et al.. “Identification of Subclinical Heart Failure With Preserved Ejection Fraction in Patients With Symptomatic Atrial Fibrillation.” JACC. Heart failure (2023). PMID: 37676212 ↗

    L2OTHERCited in: Interventional and Device Therapy
  467. [467]

    Marques P, Travlos CK, Matias P et al.. “Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices.” JACC. Heart failure (2025). PMID: 40992090 ↗

    L2OTHERCited in: Interventional and Device Therapy
  468. [468]

    Bola H, Arif A, J Hon J et al.. “Cryoballoon Versus Radiofrequency Ablation for Persistent Atrial Fibrillation: Meta-Analysis of Randomized Trials.” Pacing and clinical electrophysiology : PACE (2026). PMID: 42397058 ↗

    L1SR_OBSCited in: Interventional and Device Therapy, Prognosis and Natural History
  469. [469]

    Bacha Z, Javed J, Khan MH et al.. “Comparative effectiveness of figure-of-eight suture and manual compression for femoral venous hemostasis after atrial fibrillation ablation: A grade assessed meta-analysis.” Journal of thrombosis and thrombolysis (2026). PMID: 42384139 ↗

    L5SR_OBSCited in: Interventional and Device Therapy
  470. [470]

    Irnizarifka I, Tristan CD, Budiono EA et al.. “Feasibility of pulsed field ablation for ventricular arrhythmia: a systematic review.” Future cardiology (2026). PMID: 42434806 ↗

    L4SR_OBSCited in: Interventional and Device Therapy, Complications
  471. [471]

    Oldgren J, Åsberg S, Hijazi Z et al.. “Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study.” Circulation (2022). PMID: 36065821 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Prognosis and Natural History
  472. [472]

    Joosten LPT, van Doorn S, van de Ven PM et al.. “Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.” Circulation (2023). PMID: 37634130 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention
  473. [473]

    Holmes DR, Kar S, Price MJ et al.. “Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.” Journal of the American College of Cardiology (2014). PMID: 24998121 ↗

    L1RCTCited in: History and Evolution of Treatment
  474. [474]

    Filippatos G, Bakris GL, Pitt B et al.. “Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.” Journal of the American College of Cardiology (2021). PMID: 34015478 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention
  475. [475]

    Verma S, Butler J, Borlaug BA et al.. “Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.” Journal of the American College of Cardiology (2024). PMID: 39217565 ↗

    L1RCTCited in: History and Evolution of Treatment
  476. [476]

    Papi A, Vestbo J, Fabbri L et al.. “Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.” Lancet (London, England) (2018). PMID: 29429593 ↗

    L1RCTCited in: History and Evolution of Treatment
  477. [477]

    Heerspink HJL, Kiyosue A, Wheeler DC et al.. “Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.” Lancet (London, England) (2023). PMID: 37931629 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Special Populations and Prevention
  478. [478]

    Krisai P, Belley-Cote EP, McIntyre WF et al.. “Heart failure after left atrial appendage occlusion: Insights from the LAAOS III randomized trial.” European journal of heart failure (2024). PMID: 39586754 ↗

    L1RCTCited in: History and Evolution of Treatment
  479. [479]

    Butt JH, Docherty KF, Jhund PS et al.. “Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF.” European journal of heart failure (2021). PMID: 34766424 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Prognosis and Natural History
  480. [480]

    Maron BJ. “Hypertrophic cardiomyopathy: a systematic review.” JAMA (2002). PMID: 11886323 ↗

    L5SR_OBSCited in: History and Evolution of Treatment
  481. [481]

    McQuilten ZK, Thao LTP, Bick AG et al.. “Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin.” JAMA cardiology (2025). PMID: 41091476 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Populations and Prevention
  482. [482]

    Yang Z, Tiemuerniyazi X, Xu F et al.. “Partial Cardiac Denervation to Prevent Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: The pCAD-POAF Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 39550720 ↗

    L1RCTCited in: History and Evolution of Treatment
  483. [483]

    Siegal DM, Sticherling C, Healey JS et al.. “Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 41222953 ↗

    L1RCTCited in: History and Evolution of Treatment
  484. [484]

    Nassif ME, Windsor SL, Gosch K et al.. “Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.” Circulation. Heart failure (2023). PMID: 37203441 ↗

    L1RCTCited in: History and Evolution of Treatment
  485. [485]

    Oluleye OW, Rector TS, Win S et al.. “History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction.” Circulation. Heart failure (2014). PMID: 25225241 ↗

    L2RCTCited in: History and Evolution of Treatment, Prognosis and Natural History
  486. [486]

    Jering KS, Claggett BL, Pfeffer MA et al.. “Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial.” Circulation. Heart failure (2023). PMID: 37125529 ↗

    L2RCTCited in: History and Evolution of Treatment
  487. [487]

    Zakeri R, Borlaug BA, McNulty SE et al.. “Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.” Circulation. Heart failure (2013). PMID: 24162898 ↗

    L2RCTCited in: History and Evolution of Treatment
  488. [488]

    van Diepen S, Hellkamp AS, Patel MR et al.. “Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.” Circulation. Heart failure (2013). PMID: 23723250 ↗

    L1RCTCited in: History and Evolution of Treatment
  489. [489]

    Diet F, Erdmann E. “Thromboembolism in heart failure: who should be treated?” European journal of heart failure (2000). PMID: 11113711 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  490. [490]

    Mi X, Wang T, Ye W et al.. “Impact of hypertension history and blood pressure parameters on cognitive impairment in patients with atrial fibrillation: a systematic review and meta-analysis.” Frontiers in cardiovascular medicine (2026). PMID: 42311763 ↗

    L2SR_OBSCited in: History and Evolution of Treatment
  491. [491]

    Thangjui S, Knutsen K, Hollowell B et al.. “Natural history and outcomes of post-operative atrial fibrillation after non-cardiac surgery: a clinically adjudicated single-center retrospective study.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 42370998 ↗

    L3COHORTCited in: History and Evolution of Treatment
  492. [492]

    Elshazly MB, Wilkoff BL, Tarakji K et al.. “Exercise Ventricular Rates, Cardiopulmonary Exercise Performance, and Mortality in Patients With Heart Failure With Atrial Fibrillation.” Circulation. Heart failure (2021). PMID: 33478244 ↗

    L3OTHERCited in: History and Evolution of Treatment
  493. [493]

    Parikh VN, Caleshu C, Reuter C et al.. “Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy.” Circulation. Heart failure (2019). PMID: 30871351 ↗

    L4OTHERCited in: History and Evolution of Treatment
  494. [494]

    Sanchis-Gomar F, Lavie CJ, Lippi G. “Global epidemiology of atrial fibrillation and atrial flutter: An increasing worldwide burden.” International journal of stroke : official journal of the International Stroke Society (2026). PMID: 42332406 ↗

    L2REVIEW_NARRATIVECited in: History and Evolution of Treatment
  495. [495]

    Shukkoor AA, Turgeon RD, De Vera MA et al.. “Association of ischaemic stroke/TIA with subsequent oral anticoagulant adherence in patients with atrial fibrillation: a scoping review.” BMJ open (2026). PMID: 42331577 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  496. [496]

    Gencer B, Djousse L, Al-Ramady OT et al.. “Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.” Circulation (2021). PMID: 34612056 ↗

    L1SR_MA_RCTCited in: Complications, Prognosis and Natural History
  497. [497]

    Butt JH, Jhund PS, Henderson AD et al.. “Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.” European journal of heart failure (2025). PMID: 40222820 ↗

    L1RCTCited in: Complications
  498. [498]

    Triposkiadis F, Pieske B, Butler J et al.. “Global left atrial failure in heart failure.” European journal of heart failure (2016). PMID: 27813305 ↗

    L5REVIEW_NARRATIVECited in: Complications
  499. [499]

    Alzubi AS, Abdelaziz AM, Chukr M et al.. “Meta-analysis of the safety of outpatient Sotalol initiation in clinical practice.” Indian pacing and electrophysiology journal (2026). PMID: 42372971 ↗

    L2SR_OBSCited in: Complications
  500. [500]

    McIntyre WF, Benz AP, Becher N et al.. “Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.” Circulation (2023). PMID: 37952187 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  501. [501]

    Kuno T, Takagi H, Ando T et al.. “Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis.” Journal of the American College of Cardiology (2020). PMID: 31976865 ↗

    L2SR_OBSCited in: Prognosis and Natural History
  502. [502]

    Milling TJ, Middeldorp S, Xu L et al.. “Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.” Circulation (2023). PMID: 36802876 ↗

    L4TRIAL_NONRANDOMCited in: Prognosis and Natural History
  503. [503]

    Connolly SJ, Ezekowitz MD, Yusuf S et al.. “Dabigatran versus warfarin in patients with atrial fibrillation.” The New England journal of medicine (2009). PMID: 19717844 ↗

    L1RCTCited in: Prognosis and Natural History
  504. [504]

    Rienstra M, Damman K, Mulder BA et al.. “Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis.” JACC. Heart failure (2013). PMID: 24621795 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  505. [505]

    Mebazaa A, Nieminen MS, Packer M et al.. “Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.” JAMA (2007). PMID: 17473298 ↗

    L1RCTCited in: Prognosis and Natural History
  506. [506]

    Zeldin L, Eichler JBS, Teruya SL et al.. “Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy.” European journal of heart failure (2024). PMID: 39638976 ↗

    L3OTHERCited in: Prognosis and Natural History
  507. [507]

    Perdeck J, Knops RE, de Groot JR et al.. “Predicted adherence and ischaemic stroke risk in atrial fibrillation patients initiating oral anticoagulation: A cohort study of the medication adherence score.” International journal of cardiology (2026). PMID: 42401295 ↗

    L3COHORTCited in: Prognosis and Natural History
  508. [508]

    Chyou JY, Tay WT, Tromp J et al.. “Prognostic Implications and Global Perspectives of Atrial Fibrillation in Patients Hospitalized for Heart Failure.” JACC. Heart failure (2025). PMID: 39918534 ↗

    L2OTHERCited in: Prognosis and Natural History
  509. [509]

    Ndumele CE, Rodriguez F, Dixon DL et al.. “2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2026). PMID: 42265997 ↗

    L1GUIDELINECited in: Special Populations and Prevention
  510. [510]

    Ommen SR, Mital S, Burke MA et al.. “2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2020). PMID: 33215938 ↗

    L1GUIDELINECited in: Special Populations and Prevention
  511. [511]

    Ommen SR, Ho CY, Asif IM et al.. “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2024). PMID: 38727647 ↗

    L1GUIDELINECited in: Special Populations and Prevention
  512. [512]

    Arnett DK, Blumenthal RS, Albert MA et al.. “2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2019). PMID: 30894319 ↗

    L1GUIDELINECited in: Special Populations and Prevention
  513. [513]

    Heidenreich PA, Bozkurt B, Aguilar D et al.. “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2022). PMID: 35379504 ↗

    L1GUIDELINECited in: Special Populations and Prevention
  514. [514]

    Miyauchi K, Iwata H, Nishizaki Y et al.. “Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA).” Circulation (2024). PMID: 38873793 ↗

    L1RCTCited in: Special Populations and Prevention
  515. [515]

    Kapadia SR, Krishnaswamy A, Whisenant B et al.. “Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation.” Circulation (2023). PMID: 37874908 ↗

    L1RCTCited in: Special Populations and Prevention
  516. [516]

    Nicolau AM, Giugliano RP, Zimerman A et al.. “Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE-AF Substudy.” Journal of the American College of Cardiology (2025). PMID: 40769671 ↗

    L1RCTCited in: Special Populations and Prevention
  517. [517]

    Huang H, Liu Y, Shuai W et al.. “Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial.” European heart journal (2024). PMID: 39178138 ↗

    L1RCTCited in: Special Populations and Prevention
  518. [518]

    Okumura K, Akao M, Yoshida T et al.. “Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.” The New England journal of medicine (2020). PMID: 32865374 ↗

    L1RCTCited in: Special Populations and Prevention
  519. [519]

    Mas JL, Derumeaux G, Guillon B et al.. “Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.” The New England journal of medicine (2017). PMID: 28902593 ↗

    L1RCTCited in: Special Populations and Prevention
  520. [520]

    Søndergaard L, Kasner SE, Rhodes JF et al.. “Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.” The New England journal of medicine (2017). PMID: 28902580 ↗

    L1RCTCited in: Special Populations and Prevention
  521. [521]

    Zheng Z, Jayaram R, Jiang L et al.. “Perioperative Rosuvastatin in Cardiac Surgery.” The New England journal of medicine (2016). PMID: 27144849 ↗

    L1RCTCited in: Special Populations and Prevention
  522. [522]

    Wazni OM, Dandamudi G, Sood N et al.. “Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation.” The New England journal of medicine (2020). PMID: 33197158 ↗

    L1RCTCited in: Special Populations and Prevention
  523. [523]

    Yusuf S, Healey JS, Pogue J et al.. “Irbesartan in patients with atrial fibrillation.” The New England journal of medicine (2011). PMID: 21388310 ↗

    L1RCTCited in: Special Populations and Prevention
  524. [524]

    Heneghan C, Ward A, Perera R et al.. “Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data.” Lancet (London, England) (2011). PMID: 22137798 ↗

    L1SR_OBSCited in: Special Populations and Prevention
  525. [525]

    d'Arcy JL, Coffey S, Loudon MA et al.. “Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study.” European heart journal (2016). PMID: 27354049 ↗

    L2COHORTCited in: Special Populations and Prevention
  526. [526]

    Kumar RK, Antunes MJ, Beaton A et al.. “Contemporary Diagnosis and Management of Rheumatic Heart Disease: Implications for Closing the Gap: A Scientific Statement From the American Heart Association.” Circulation (2020). PMID: 33073615 ↗

    L1REVIEW_NARRATIVECited in: Special Populations and Prevention
  527. [527]

    Siscovick DS, Barringer TA, Fretts AM et al.. “Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association.” Circulation (2017). PMID: 28289069 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  528. [528]

    Stewart S, Ball J, Horowitz JD et al.. “Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial.” Lancet (London, England) (2014). PMID: 25467562 ↗

    L1RCTCited in: Special Populations and Prevention
  529. [529]

    Bousser MG, Bouthier J, Büller HR et al.. “Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.” Lancet (London, England) (2008). PMID: 18294998 ↗

    L1RCTCited in: Special Populations and Prevention
  530. [530]

    Macle L, Khairy P, Weerasooriya R et al.. “Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial.” Lancet (London, England) (2015). PMID: 26211828 ↗

    L1RCTCited in: Special Populations and Prevention
  531. [531]

    Mullens W, Dauw J, Martens P et al.. “Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics.” European journal of heart failure (2022). PMID: 35733283 ↗

    L4RCTCited in: Special Populations and Prevention
  532. [532]

    Cheng L, Hammersley D, Ragavan A et al.. “Long-term follow-up of the TRED-HF trial: Implications for therapy in patients with dilated cardiomyopathy and heart failure remission.” European journal of heart failure (2024). PMID: 39349993 ↗

    L2RCTCited in: Special Populations and Prevention
  533. [533]

    Mulder BA, van Veldhuisen DJ, Crijns HJ et al.. “Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS.” European journal of heart failure (2012). PMID: 22764183 ↗

    L2RCTCited in: Special Populations and Prevention
  534. [534]

    Kirchhof P, Calkins H. “Catheter ablation in patients with persistent atrial fibrillation.” European heart journal (2016). PMID: 27389907 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  535. [535]

    Ajjan RA, Kietsiriroje N, Badimon L et al.. “Antithrombotic therapy in diabetes: which, when, and for how long?” European heart journal (2021). PMID: 33764414 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  536. [536]

    van den Berg MP, Mulder BA, Klaassen SHC et al.. “Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.” European heart journal (2019). PMID: 30753432 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  537. [537]

    Patel SM, Giugliano RP, Morrow DA et al.. “Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 40888686 ↗

    L2RCTCited in: Special Populations and Prevention
  538. [538]

    Hijazi Z, Hohnloser SH, Andersson U et al.. “Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.” JAMA cardiology (2016). PMID: 27438322 ↗

    L2RCTCited in: Special Populations and Prevention
  539. [539]

    Sliwa K, Azibani F, Johnson MR et al.. “Effectiveness of Implanted Cardiac Rhythm Recorders With Electrocardiographic Monitoring for Detecting Arrhythmias in Pregnant Women With Symptomatic Arrhythmia and/or Structural Heart Disease: A Randomized Clinical Trial.” JAMA cardiology (2020). PMID: 32074256 ↗

    L1RCTCited in: Special Populations and Prevention
  540. [540]

    Steinberg JS, Shabanov V, Ponomarev D et al.. “Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial.” JAMA (2020). PMID: 31961420 ↗

    L1RCTCited in: Special Populations and Prevention
  541. [541]

    Ahmed S, Rienstra M, Crijns HJ et al.. “Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial.” JAMA (2008). PMID: 18854540 ↗

    L1RCTCited in: Special Populations and Prevention
  542. [542]

    Lam CS, Carson PE, Anand IS et al.. “Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.” Circulation. Heart failure (2012). PMID: 22887722 ↗

    L2RCTCited in: Special Populations and Prevention
  543. [543]

    Gomez KA, Tromp J, Figarska SM et al.. “Distinct Comorbidity Clusters in Patients With Acute Heart Failure: Data From RELAX-AHF-2.” JACC. Heart failure (2024). PMID: 38970586 ↗

    L2RCTCited in: Special Populations and Prevention
  544. [544]

    Steinberg BA, Al-Khatib SM, Edwards R et al.. “Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials.” JACC. Heart failure (2014). PMID: 25306452 ↗

    L2SR_OBSCited in: Special Populations and Prevention
  545. [545]

    Mehta R, Cai X, Lee J et al.. “Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.” JAMA cardiology (2016). PMID: 27434583 ↗

    L2COHORTCited in: Special Populations and Prevention
  546. [546]

    Cheng X, Song C, Ouyang F et al.. “Systolic blood pressure variability: risk of cardiovascular events, chronic kidney disease, dementia, and death.” European heart journal (2025). PMID: 40249367 ↗

    L2OTHERCited in: Special Populations and Prevention
  547. [547]

    Taageby Nielsen S, Luo J, Tybjærg-Hansen A et al.. “Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study.” European heart journal (2025). PMID: 40900121 ↗

    L2OTHERCited in: Special Populations and Prevention
  548. [548]

    González-López E, Gallego-Delgado M, Guzzo-Merello G et al.. “Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.” European heart journal (2015). PMID: 26224076 ↗

    L4OTHERCited in: Special Populations and Prevention
  549. [549]

    Wu X, Meng J, Yang Y et al.. “Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis.” Renal failure (2026). PMID: 42128628 ↗

    L1SR_OBSCited in: Special Populations and Prevention
  550. [550]

    Eikelboom JW, Quinlan DJ, Hirsh J et al.. “Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.” JAMA cardiology (2017). PMID: 28355459 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  551. [551]

    Berbert GH, Andalaft RB, Valdigem BP et al.. “Cilostazol for heart rate increase in atrial fibrillation with slow ventricular response: an exploratory randomized controlled trial.” European heart journal open (2026). PMID: 42146871 ↗

    L1RCTCited in: Special Populations and Prevention
  552. [552]

    Al-Shammari AS, Amin AM, Awashra A et al.. “Clinical outcomes after catheter ablation for atrial fibrillation in elderly patients: a meta-analysis with time-to-event data reconstruction.” Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing (2026). PMID: 42340581 ↗

    L2SR_OBSCited in: Special Populations and Prevention
  553. [553]

    Porcari A, Razvi Y, Masi A et al.. “Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.” European journal of heart failure (2023). PMID: 36644836 ↗

    L2OTHERCited in: Special Populations and Prevention
  554. [554]

    Dhont S, Moura-Ferreira S, Bekhuis Y et al.. “Comparative Value of HFpEF Scores for Risk Stratification in Patients with Unexplained Dyspnea.” European journal of heart failure (2026). PMID: 41802264 ↗

    L2OTHERCited in: Special Populations and Prevention
  555. [555]

    Spagnolin M, Fazzini L, Giaccherini C et al.. “Outcome trajectories in hospitalized heart failure with preserved ejection fraction: a machine learning cluster analysis.” European journal of heart failure (2026). PMID: 41740597 ↗

    L2OTHERCited in: Special Populations and Prevention
  556. [556]

    Siddiqi TJ, Anker SD, Filippatos G et al.. “Health status across major subgroups of patients with heart failure and preserved ejection fraction.” European journal of heart failure (2023). PMID: 36974746 ↗

    L1OTHERCited in: Special Populations and Prevention
  557. [557]

    Yang H, Negishi K, Wang Y et al.. “Echocardiographic screening for non-ischaemic stage B heart failure in the community.” European journal of heart failure (2016). PMID: 27813300 ↗

    L2OTHERCited in: Special Populations and Prevention
  558. [558]

    Elkind MSV. “Prevention of Stroke.” Continuum (Minneapolis, Minn.) (2026). PMID: 42233818 ↗

    L5CASE_REPORTCited in: Special Populations and Prevention
  559. [559]

    Ballin M, Carlsson AC, Wändell P et al.. “Adolescent Cardiorespiratory Fitness and the Trade-Off Between Atrial Fibrillation Risk and Cardiovascular Benefits: A Nationwide Sibling-Controlled Cohort Study.” Circulation (2026). PMID: 42165142 ↗

    L2COHORTCited in: Special Populations and Prevention
  560. [560]

    Crump C, Wei J, Sundquist J et al.. “Adverse Pregnancy Outcomes and Long-Term Risk of Atrial Fibrillation.” JAMA cardiology (2025). PMID: 41123920 ↗

    L2OTHERCited in: Special Populations and Prevention
  561. [561]

    Mo X, Janszky I, Wang H et al.. “Maternal Diabetes and Risk of Early-Onset Cardiovascular Diseases in Offspring.” JAMA cardiology (2026). PMID: 42126857 ↗

    L2OTHERCited in: Special Populations and Prevention
  562. [562]

    Carrero JJ, Evans M, Szummer K et al.. “Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.” JAMA (2014). PMID: 24595776 ↗

    L2OTHERCited in: Special Populations and Prevention
  563. [563]

    Barasch E, Gottdiener JS, Aurigemma G et al.. “Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study.” Circulation. Heart failure (2009). PMID: 19808353 ↗

    L3OTHERCited in: Special Populations and Prevention
  564. [564]

    Januzzi JL, Packer M, Claggett B et al.. “IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.” Circulation. Heart failure (2018). PMID: 30354399 ↗

    L1OTHERCited in: Special Populations and Prevention
  565. [565]

    Lanfear DE, Luzum JA, She R et al.. “Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.” Circulation. Heart failure (2020). PMID: 33012170 ↗

    L2OTHERCited in: Special Populations and Prevention
  566. [566]

    Goyal A, Norton CR, Thomas TN et al.. “Predictors of incident heart failure in a large insured population: a one million person-year follow-up study.” Circulation. Heart failure (2010). PMID: 20798277 ↗

    L2OTHERCited in: Special Populations and Prevention
  567. [567]

    Murad K, Goff DC, Morgan TM et al.. “Burden of Comorbidities and Functional and Cognitive Impairments in Elderly Patients at the Initial Diagnosis of Heart Failure and Their Impact on Total Mortality: The Cardiovascular Health Study.” JACC. Heart failure (2015). PMID: 26160370 ↗

    L2OTHERCited in: Special Populations and Prevention
  568. [568]

    Patel N, Ju C, Macon C et al.. “Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry.” JACC. Heart failure (2016). PMID: 26874392 ↗

    L2OTHERCited in: Special Populations and Prevention
  569. [569]

    Lu J, Sun S, Shang X et al.. “Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.” International journal of medical sciences (2026). PMID: 42328113 ↗

    L2SR_OBSCited in: Special Populations and Prevention
  570. [570]

    Littman E, Bukhari S, Watts H et al.. “Beyond the Coronaries: Utility of Extra-Coronary Calcification for Cardiovascular Risk Assessment in Women.” Current atherosclerosis reports (2026). PMID: 42189365 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  571. [571]

    Johner N, Gencer B. “Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation.” European journal of clinical investigation (2026). PMID: 42148709 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  572. [572]

    Laterra G, Scalia L, Strazzieri O et al.. “Left Atrial Appendage Occlusion in the Era of Minimalist Approaches: Anesthesia and Imaging Considerations.” Journal of clinical medicine (2026). PMID: 42123128 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  573. [573]

    Josey GC, Cohen J, Scheinuk JE et al.. “Sex Differences in Clinical Outcomes Among Patients With Myocarditis-Associated Cardiogenic Shock: A Retrospective Multi-Center Cohort Study.” The American journal of cardiology (2026). PMID: 42208717 ↗

    L2COHORTCited in: Special Populations and Prevention
  574. [574]

    Bu F, Xu B, Han Y et al.. “Development of risk prediction model for new-onset atrial fibrillation in elderly patients undergoing video-assisted thoracoscopic surgery: a retrospective cohort study.” Journal of thoracic disease (2026). PMID: 42182761 ↗

    L2COHORTCited in: Special Populations and Prevention

Revision History

All updates applied to this page

Loading revisions…